US20200147280A1 - Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds - Google Patents
Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds Download PDFInfo
- Publication number
- US20200147280A1 US20200147280A1 US16/733,055 US202016733055A US2020147280A1 US 20200147280 A1 US20200147280 A1 US 20200147280A1 US 202016733055 A US202016733055 A US 202016733055A US 2020147280 A1 US2020147280 A1 US 2020147280A1
- Authority
- US
- United States
- Prior art keywords
- microstrain
- manifold
- shaped projections
- shaped
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title abstract description 17
- 239000000463 material Substances 0.000 claims description 23
- 239000012530 fluid Substances 0.000 claims description 21
- 229920001971 elastomer Polymers 0.000 claims description 7
- 239000000806 elastomer Substances 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 4
- 229920002988 biodegradable polymer Polymers 0.000 claims description 3
- 239000004621 biodegradable polymer Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 abstract description 119
- 238000007789 sealing Methods 0.000 abstract description 36
- 206010052428 Wound Diseases 0.000 description 104
- 208000027418 Wounds and injury Diseases 0.000 description 104
- 210000001519 tissue Anatomy 0.000 description 80
- 210000002615 epidermis Anatomy 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000003466 welding Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000004568 cement Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000006261 foam material Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000002706 hydrostatic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000001053 micromoulding Methods 0.000 description 2
- 238000009581 negative-pressure wound therapy Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- QNIRRHUUOQAEPB-UHFFFAOYSA-N 2-(prop-2-enoylamino)butane-2-sulfonic acid Chemical compound CCC(C)(S(O)(=O)=O)NC(=O)C=C QNIRRHUUOQAEPB-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 229920002943 EPDM rubber Polymers 0.000 description 1
- 229920000181 Ethylene propylene rubber Polymers 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 229920000459 Nitrile rubber Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920002681 hypalon Polymers 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
-
- A61M1/0088—
-
- A61F13/00068—
-
- A61F13/0216—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
- A61H39/04—Devices for pressing such points, e.g. Shiatsu or Acupressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H7/00—Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for
-
- A61M1/0023—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/91—Suction aspects of the dressing
- A61M1/915—Constructional details of the pressure distribution manifold
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
Definitions
- the present invention relates generally to medical treatment systems and, more particularly, to reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds.
- Negative pressure therapy has been used to promote healing across a wide range of wound types.
- an open-cell foam is placed directly into the wound bed.
- a drape is then used to cover the dressing and seal the wound.
- the sealing member is then fluidly coupled to a reduced-pressure therapy unit to provide negative pressure, or reduced pressure, to the wound through the foam. While this approach has produced meaningful results, shortcomings and areas of desired of improvement remain.
- a reduced-pressure wound treatment system for treating tissue on a patient includes a microstrain-inducing manifold for disposing proximate the tissue that includes a plurality of shaped projections for creating microstrain within the tissue, a sealing member for placing over the tissue and microstrain-inducing manifold and operable to form a fluid seal over the tissue and microstrain-inducing manifold, and a reduced-pressure subsystem for delivering a reduced pressure to the sealing member.
- the shaped projections comprise tapered projections.
- a microstrain-inducing manifold for treating tissue on a patient includes a plurality of shaped projections for creating microstrain within the tissue.
- the shaped projections comprise tapered projections.
- a reduced-pressure wound treatment system for treating tissue on a patient includes a microstrain-inducing manifold for disposing proximate the tissue.
- the microstrain-inducing manifold includes a plurality of interconnected nodes. At least one of the interconnected nodes includes at least one shaped projection for creating microstrain within the tissue.
- the shaped projection may be an angled projection.
- the system further includes a sealing member for placing over the tissue and manifold. The sealing member is operable to form a fluid seal over the tissue and microstrain-inducing manifold.
- the system further includes a reduced-pressure subsystem for delivering a reduced pressure to the sealing member.
- a microstrain-inducing manifold for treating tissue on a patient includes a plurality of interconnected nodes. At least one of the interconnected nodes includes at least one shaped projection for creating microstrain within the tissue.
- the shaped projection may be an angled projection.
- a method for treating tissue on a patient includes placing a microstrain-inducing manifold proximate the tissue of the patient.
- the microstrain-inducing manifold includes a plurality of shaped projections for creating microstrain within the tissue.
- the shaped projections may be tapered projections.
- the method further includes disposing a sealing member over the microstrain-inducing manifold and the patient's epidermis; forming a fluid seal between the sealing member and the patient's epidermis; and providing reduced pressure to the microstrain-inducing manifold whereby the plurality of shaped projections create microstrain within the tissue.
- FIG. 1 is a schematic, perspective view of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system for treating a wound on a patient shown over a wound;
- FIG. 2 is a schematic, cross-sectional view of a portion of the system of FIG. 1 taken along line 2 - 2 in FIG. 1 ;
- FIG. 3A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a tissue site, such as a wound, on a patient as part of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system;
- FIG. 3B is an enlarged detail of the perspective view of FIG. 3A ;
- FIG. 3C is a side view of a portion of an interconnected node and shaped projection of the microstrain-inducing manifold shown in FIGS. 3A and 3B ;
- FIG. 4A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a tissue site;
- FIG. 4B is a schematic, top view of the microstrain-inducing manifold of FIG. 4A ;
- FIG. 5A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a wound on a patient;
- FIG. 5B is an enlarged partial view of the microstrain-inducing manifold of FIG. 5A ;
- FIG. 6A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a wound on a patient as part of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system;
- FIG. 6B is an enlarged partial view of the microstrain-inducing manifold of FIG. 6A ;
- FIG. 7 is a schematic, side view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold.
- tissue site 103 may be, for example, a wound 102 , or damaged area of tissue, on a patient.
- the tissue site 103 may be the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue. Unless otherwise indicated, as used herein, “or” does not require mutual exclusivity.
- the reduced-pressure wound treatment system 100 is shown in the context of the wound 102 , it will be appreciated that the reduced-pressure wound treatment system 100 may be used to treat many different types of tissue sites 103 and wounds including area wounds, incisions, internal wounds, or other tissue sites.
- the reduced-pressure wound treatment system 100 is shown on the wound 102 , which is through the epidermis 104 , or generally skin, and the dermis 106 and reaching into a hypodermis, or subcutaneous tissue 108 .
- the reduced-pressure wound treatment system 100 generally includes a sealing member 110 , a microstrain-inducing manifold 112 , and a reduced-pressure subsystem 114 .
- the microstrain-inducing manifold 112 induces microstrain and may be referred to as a microstrain-inducing manifold.
- the microstrain-inducing manifold 112 has a first side 113 and a second, patient-facing side 115 .
- microstrain results from pressure distributed with the microstrain-inducing manifold 112 to a tissue site 103 , such as a wound surface 105 of the wound 102 . It is believed that this action creates areas of cell surface strain, or microdeformation.
- the cells appear to respond to the strain by expressing special receptors on the surface of the cells and turning on genetic pathways in the cells, which promote healing activities.
- the healing activities may include increased metabolic activity, stimulation of fibroblast migration, increased cellular proliferation, extra cellular matrix production, and the formation of granulation tissue, as well as a decrease in edema and a subsequent improvement of perfusion at the tissue site 103 .
- granulation tissue fills the wound 102 and thereby further reduces volume and prepares the wound 102 for final closure by secondary or delayed primary intention.
- the sealing member 110 is generally formed from a flexible sheet.
- the sealing member 110 includes a first surface 120 and a patient-facing surface 122 .
- the sealing member 110 may be sized so that the sealing member 110 overlaps the wound 102 in such a manner that a drape extension 116 extends beyond the peripheral edge of the wound 102 .
- the sealing member 110 may be formed from any material that provides a fluid seal.
- fluid seal or “seal,” means a seal adequate to maintain reduced pressure at a desired site, e.g., a tissue site, given the particular reduced-pressure source involved.
- the sealing member may, for example, be an impermeable or semi-permeable, elastomeric material.
- “Elastomeric” means having the properties of an elastomer. Elastomeric generally refers to a polymeric material that has rubber-like properties. More specifically, most elastomers have ultimate elongations greater than 100% and a significant amount of resilience. The resilience of a material refers to the material's ability to recover from an elastic deformation.
- elastomers may include, but are not limited to, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones.
- sealing member materials include a silicone drape, 3M Tegaderm® drape, acrylic drape such as one available from Avery Dennison, or an incise drape.
- An attachment member 118 or device may be coupled to the sealing member 110 .
- the attachment member 118 is operable to removably couple the sealing member 110 to a patient's epidermis 104 .
- the term “coupled” includes coupling via a separate object and includes direct coupling.
- the term “coupled” also encompasses two or more components that are continuous with one another by virtue of each of the components being formed from the same piece of material.
- the term “coupled” may include chemical, such as via a chemical bond, mechanical, thermal, or electrical coupling.
- Fluid coupling means that fluid is in communication between the designated parts or locations.
- the sealing member 110 and attachment member 118 work together to form a fluid seal over the patient's epidermis 104 .
- the attachment member 118 may be any material suitable to help couple the sealing member 110 to a patient's epidermis 104 .
- the attachment member 118 may be a pressure-sensitive adhesive, heat-activated adhesive, sealing tape, double-sided sealing tape, paste, hydrocolloid, hydrogel, hooks, sutures, etc.
- the attachment member 118 is an adhesive layer 119 coupled to the patient-facing surface 122 of the drape extension 116 .
- the attachment member 118 may span the entire width or a portion of the patient-facing surface 122 of the sealing member 110 .
- the attachment member 118 may be applied over the entire first surface 120 of the sealing member 110 , or over the first surface of the drape extensions 116 .
- the microstrain-inducing manifold 112 is typically positioned between the second, patient-facing surface 122 of the sealing member 110 and the tissue site 103 , e.g., the wound 102 .
- the microstrain-inducing manifold 112 may be sized to approximate the estimated area of the wound 102 , although a larger or smaller size may be used in different applications.
- the microstrain-inducing manifold 112 includes a plurality of interconnected nodes 124 .
- the interconnected nodes 124 may have a substantially circular cross-section, but it will be appreciated that the interconnected nodes 124 may have any suitable cross-section including, but not limited to, triangular, square, rectangular, hexagonal, octagonal, elliptical, etc.
- Each interconnected node 124 may include one or more shaped projections 126 .
- the shaped projections 126 are operable to create microstrain at the cellular level within the tissue site 103 , e.g., the wound 102 . While the illustrative embodiment shows each interconnected node 124 having a plurality of shaped projections 126 , it will be appreciated that some interconnected nodes 124 may be formed to avoid creating microstrains in certain areas. For example, one or more shaped projections 126 may be formed with a lower profile in a certain area or be absent all together in certain areas.
- an additional manifold with no shaped projections e.g., a smooth, laminar manifold, may be placed between at least a portion of the shaped projections 126 of the microstrain-inducing manifold 112 and a portion of the tissue site 103 to prevent the creation of strain in a certain area. It is believed that avoiding microstrains in certain areas is helpful to overall patient care.
- microstrain-inducing manifold 112 without projections 126 or that does not create microstrains in certain areas if a portion of the microstrain-inducing manifold 112 will lay on top of a vein, an artery, graft(s), objects used for adjunctive treatment or therapy (e.g., stents), exposed organs (e.g., heart or bowel), etc.
- objects used for adjunctive treatment or therapy e.g., stents
- exposed organs e.g., heart or bowel
- the shaped projections 126 may be substantially the same size. Alternatively, some projections 126 may be larger or smaller than others. In one alternative, some shaped projections 126 may have a larger pitch than others, where “pitch” is defined by the angle 128 between a reference line 127 formed to have a right angle with a longitudinal axis 129 of the shaped projection 126 as shown in cross section in FIG. 3C . Each shaped projection 126 has an outer surface 130 and a base 132 .
- the shaped projections 126 in the illustrative embodiment are conical in shape, it will be appreciated that the shaped projections 126 may have any suitable shape capable of creating a microstrain within the wound 102 ; for example, the shaped projections 126 may be substantially cube shaped, pyramid shaped, hemispherically shaped, cylindrically shaped, triangularly shaped, cylindrically shaped with a distal recess, tapered, more elaborately shaped, etc.
- the shaped projections 126 are typically angled or tapered from a thick proximal end to a thin distal end or vice versa.
- the shaped projections 126 are formed of the same material as the interconnected nodes 124 .
- the shaped projections 126 may be formed from a different material or the same material type of material with different properties than the interconnected nodes 124 or the other shaped projections 126 . Via material selection, one may control the stiffness of the interconnected nodes 124 such that greater microstrain may be provided in certain areas of the wound 102 versus others.
- the interconnected nodes 124 , shaped projections 126 , and the microstrain-inducing manifold 112 generally may be formed of a foam material or a non-foam material.
- the interconnected nodes 124 may be interconnected using a network of connecting members 134 .
- the network of connecting members 134 may include a plurality of members 136 with each member 136 coupling adjacent interconnected nodes 124 to one another.
- the members 136 have a substantially circular cross-section; however, it will be appreciated that the members 136 may have any suitable cross-section, including, but not limited to, triangular, square, rectangular, hexagonal, octagonal, elliptical, etc.
- the connecting members 134 may be configured such that the microstrain-inducing manifold 112 behaves anisotropically when subjected to a reduced pressure.
- the interconnected nodes 124 , connecting members 134 , and shaped projections 126 are arranged such that the microstrain-inducing manifold 112 includes a plurality of flow channels 140 ( FIG. 3B ) or pathways between the interconnected nodes 124 .
- the flow channels 140 improve distribution of fluids provided to and removed from the area of tissue around the microstrain-inducing manifold 112 .
- the microstrain-inducing manifold 112 is operable to assist in applying reduced pressure to, delivering fluids to, or removing fluids from a tissue site 103 .
- the design of microstrain-inducing manifold 112 helps to avoid painful removal caused by in-growth, i.e., when growth of granulation tissue occurs into a manifold, and allows for easier removal from the tissue site 103 .
- the microstrain-inducing manifold 112 may be formed from any suitable material.
- the microstrain-inducing manifold 112 may be formed from an elastomer, a bioabsorbable/biodegradable polymer, etc.
- the manifold material may itself be, or may be combined with, a radio opaque material or a UV florescent material such that the wound 102 may be scanned with an X-ray or UV light in order to determine whether or not any remnants of the microstrain-inducing manifold 112 remain in the wound 102 after efforts have been made to remove the microstrain-inducing manifold 112 from the wound 102 .
- the shaped projections 126 may be coated with a drug (e.g., an anticoagulant), an antimicrobial agent (e.g., silver or copper), a hydrophilic material, etc.
- a drug e.g., an anticoagulant
- an antimicrobial agent e.g., silver or copper
- a hydrophilic material e.g., a hydrophilic material
- the microstrain-inducing manifold 112 may also be formed with additional components, e.g., a delivery tube (not shown), whereby drugs or antimicrobial agents may be delivered to the wound 102 through the microstrain-inducing manifold 112 .
- the microstrain-inducing manifold 112 may be formed by any suitable process, including, but not limited to, micromolding, injection molding, casting, etc.
- the shaped projections 126 may be formed to be substantially integral with corresponding interconnected nodes 124 or may be coupled to corresponding interconnected nodes 124 by any suitable technique, including, but not limited to, mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc.
- the microstrain-inducing manifold 112 may include numerous devices for creating point pressure or otherwise inducing microstrain.
- the microstrain-inducing manifold 112 includes limited contact points with the tissue site 103 . The contact points contribute to the inducement of microstrain at the tissue site 103 .
- the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 40 percent of the surface area X (40% X).
- projection surface area means the area that a general projection of an item would make on a flat surface.
- the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 30 percent of the surface area X (30% X).
- the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 20 percent of the surface area X (20% X).
- the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 10 percent of the surface area X (10% X).
- the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 5 percent of the surface area X (5% X).
- the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 2 percent of the surface area X (2% X).
- the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 1 percent of the surface area X (1% X).
- the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 0.5 percent of the surface area X (0.5% X).
- the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 0.2 percent of the surface area X (0.2% X).
- the microstrain-inducing manifold 112 adjacent to tissue site 103 103 may cover the wound surface 105 , and may have a projection surface area X, and yet the portion of microstrain-inducing manifold 112 directly impinging on the wound surface 105 may only be 0.2 percent of X.
- the impinging portion may only be a portion of an outer surface 130 of each of the plurality of shaped projections 126 .
- the microstrain-inducing manifold 112 may be disposed proximate the wound 102 such that the interconnected nodes 124 engage the wound surface 105 .
- the microstrain-inducing manifolds 112 are stacked on top of one another to substantially fill the wound 102 .
- a single microstrain-inducing manifold 112 may be employed or a multi-layer microstrain-inducing manifold may also be formed and used.
- the microstrain-inducing manifold 112 may be formed from a single interconnected node 124 with a shaped projection 126 ; multiple independent interconnected nodes 124 with shaped projections 126 ; or a group of interconnected nodes 124 , which include shaped projections 126 , that are interconnected with the connecting members 134 .
- a single microstrain-inducing manifold 112 may be rolled up or folded over itself in order to fill the wound 102 . Furthermore, it will be appreciated that a single microstrain-inducing manifold 112 may be loaded into the wound 102 and an additional manifold placed atop the manifold 112 . Examples of additional manifolds that may be placed atop the microstrain-inducing manifold 112 include, without limitation, devices that have structural elements arranged to form flow channels, cellular foam such as open-cell foam, porous tissue collections, and liquids, gels and foams that include or cure to include flow channels.
- the reduced-pressure subsystem 114 includes a reduced-pressure source 142 , which may take many different forms.
- the reduced-pressure source 142 provides reduced pressure as a part of the reduced-pressure wound treatment system 100 .
- reduced pressure generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure at the tissue site. Reduced pressure may initially generate fluid flow in the microstrain-inducing manifold 112 , a conduit 150 , and proximate the tissue site 103 .
- the reduced pressure delivered may be static or dynamic (patterned or random) and may be delivered continuously or intermittently.
- the reduced-pressure subsystem 114 provides reduced pressure.
- the reduced-pressure subsystem 114 includes a reduced-pressure source 142 that may be any source of a reduced pressure, such a vacuum pump, wall suction, etc. While the amount and nature of reduced pressure applied to a tissue site will typically vary according to the application, the reduced pressure will typically be between ⁇ 5 mm Hg and ⁇ 500 mm Hg. Pressure may be applied to the microstrain-inducing manifold 112 in other ways as well; for example, a pressure wrap may be used.
- the reduced-pressure source 142 is shown having a battery compartment 144 and a canister region 146 with windows 148 providing a visual indication of the level of fluid within canister 146 .
- An interposed membrane filter such as hydrophobic or oleophobic filter, may be interspersed between the conduit 150 , or tubing, and the reduced-pressure source 142 .
- the reduced pressure supplied by the reduced-pressure source 142 is delivered through the conduit 150 to a reduced-pressure interface 152 , which may be an elbow port 154 .
- the port 154 is a TRAC® technology port available from Kinetic Concepts, Inc. of San Antonio, Texas.
- the reduced-pressure interface 152 allows the reduced pressure to be delivered to the sealing member 110 and realized within an interior portion of sealing member 110 as well as the microstrain-inducing manifold 112 .
- the port 154 extends through the sealing member 110 to the microstrain-inducing manifold 112 .
- the reduced-pressure wound treatment system 100 may be applied to a patient's epidermis 104 over the tissue site 103 , e.g., wound 102 .
- the microstrain-inducing manifold 112 may be disposed proximate the tissue site 103 , e.g., disposed within the wound 102 , or may overlay a portion of the wound 102 .
- the sealing member 110 may be placed over the top of the microstrain-inducing manifold 112 such that drape extensions 116 extend beyond the periphery of the wound 102 .
- the drape extensions 116 are secured to the patient's epidermis 104 (or a gasket member, such an additional piece of over drape surrounding the wound edges) by the attachment member 118 in order to form a fluid seal over the wound 102 .
- a fluid seal with the patient's epidermis shall be deemed to also include forming a seal with a gasket proximate the wound 102 .
- the reduced-pressure interface 152 is applied, if not already installed, and the conduit 150 fluidly coupled at one end to the reduced-pressure interface 152 .
- the other end of the conduit 150 is fluidly coupled to the reduced-pressure source 142 .
- the reduced-pressure source 142 may be activated such that reduced pressure is delivered to the sealing member 110 and microstrain-inducing manifold 112 .
- the reduced pressure provides reduced-pressure treatment to the tissue site 103 , removes fluids, and may force the shaped projections 126 of the microstrain-inducing manifold 112 against the wound 102 such that they create a microstrain at the cellular level within the wound 102 .
- the microstrain may promote cellular proliferation, formation of granular tissue, and other beneficial effects.
- the microstrain-inducing manifold 112 may be placed proximate the tissue site 103 and then pressure may be applied by using a wrap over the microstrain-inducing manifold 112 or other source of pressure.
- microstrain-inducing manifold 212 for use as part of a reduced-pressure wound treatment, such as the reduced-pressure wound treatment system 100 in FIG. 1 .
- the microstrain-inducing manifold 212 includes interconnected nodes 224 , which include shaped projections 226 extending from the interconnected nodes 224 .
- the shaped projections 226 are conical in shape; however, it will be appreciated that the shaped projections 226 may be any suitable shape capable of creating microstrain within a wound as previously discussed.
- each interconnected node 224 of the illustrative embodiment includes two projections 226 (one directed up and one directed down for the orientation shown in FIG. 4A ), it will be appreciated that any number of projections 224 may extend from each interconnected node 224 or that some of the interconnected nodes 224 may have no projections 224 . Also, in the illustrative embodiment, each projection 226 extends substantially normal from a corresponding interconnected node 224 , but it will be appreciated that each projection 226 may extend from the corresponding interconnected node 224 at any angle.
- the interconnected nodes 224 are spaced apart and interconnected by a network of connecting members 234 as clearly shown in FIG. 4B .
- the network of connecting members 234 includes a plurality of curved members 236 .
- a plurality of flow channels 240 are formed between the interconnected nodes 224 and members 236 .
- the members 236 have curved surfaces 290 that are curved in a cooperative manner with one another or with the radius of one or more corresponding interconnected nodes 224 such that when the microstrain-inducing manifold 212 is subjected to a reduced pressure, the microstrain-inducing manifold 212 collapses (partially or fully) in two directions (e.g., along the x-axis 286 and y-axis 288 ) but not at all or to a lesser extent in a third direction (e.g., the z-axis 284 ).
- each curved surface 290 of each member 236 abuts or approaches a curved surface 290 of an adjacent member 236 or at least one corresponding interconnected node 224 . This may be particularly advantageous if the reduced-pressure wound treatment system is configured to assist in drawing the wound together during reduced pressure therapy.
- a manifold structure 412 which is a form of a microstrain-inducing manifold.
- the manifold structure 412 is for use with a reduced-pressure wound treatment system, such as the reduced-pressure wound treatment system 100 of FIG. 1 , is shown.
- the manifold structure 412 includes one or more longitudinal members 456 .
- the longitudinal members 456 may be coupled in a spaced relationship by lateral connecting members 460 .
- the lateral connecting members 460 may be coupled to the longitudinal members 456 .
- the longitudinal members 456 and lateral connecting members 460 are shown with circular cross-sections, but it should be appreciated that the longitudinal members 456 and lateral connecting members 460 may have any suitable cross-sectional shape. While reference is made to longitudinal and lateral members, the members 456 , 460 need not be orthogonal but may have other relative angles.
- Each longitudinal member 456 of the manifold structure 412 includes one or more shaped projections 426 for creating a microstrain within a wound.
- the longitudinal members 456 and shaped projections 426 are arranged such that the manifold structure 412 includes a plurality of flow channels 440 or pathways between adjacent longitudinal members 456 or between projections 426 .
- the flow channels 440 facilitate distribution of fluids provided to and removed from the area of tissue around the manifold structure 412 .
- any combination of longitudinal members 456 and lateral members 460 may be used.
- the manifold structure 412 may be formed by a longitudinally connected group of longitudinal members 456 with projections 426 . There are eight such longitudinal groups shown in FIG.
- lateral connecting members 460 may be omitted in some embodiments.
- lateral connecting members 460 may be distributed at various locations between the longitudinal members 456 .
- each shaped projection 426 projects substantially normal from the corresponding longitudinal member 456 .
- “normal” is a vector which perpendicular to that surface. For a non-flat surface, the normal vector may be taken at a point and is the same as a normal to the tangent plane at that point. It should be appreciated, however, that each shaped projection 426 may project at any angle relative to the corresponding longitudinal member 456 .
- Each shaped projection 426 may include a columnar body 427 , which has a first outer diameter (D 1 ), and an enlarged member 429 , which has a second outer diameter (D 2 ). Each enlarged member 429 is positioned at the distal end of an associated columnar body 427 .
- Each columnar body 429 may have any shape, e.g., the cross-section may be a circular, square, elliptical, irregular, etc., and may vary along its longitudinal dimension.
- the enlarged member 429 may be a spherical member as shown or may take any other shape, such as rounded cylindrical member, a cubical member, or an irregular shape.
- the second outer diameter (D 2 ) of the enlarged member 429 is greater than the first outer diameter (D 1 ) of the columnar body 427 , i.e., D 2 >D 1 .
- the shaped projections 426 may be considered to be tapered from a larger distal end to a smaller proximal end.
- Each shaped projection 426 may have any suitable shape capable of creating a microstrain within the wound when the shaped projection 426 impinges upon the wound. Additionally, in the illustrative embodiment, the shaped projections 426 have substantially equal heights, but it will be appreciated that the shaped projections 426 may have varying heights along each longitudinal member 456 or among the plurality of longitudinal members 456 . Also, it will be appreciated that certain portions of certain longitudinal members 456 may not have shaped projections 426 such that microstrain is not provided to certain areas within the wound. As with the microstrain-inducing manifolds previously discussed, the manifold structure 412 may be formed using any suitable process, including, but not limited to, micromolding, injection molding, casting, etc.
- the shaped projections 426 may be formed to be substantially integral with corresponding longitudinal members 456 or may be coupled to corresponding longitudinal members 456 by any suitable technique including, but not limited to, mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc.
- the manifold structure 412 is placed proximate the tissue site, e.g., wound, and a sealing member is deployed over the manifold structure 412 and tissue site. Reduced pressure may then be applied or alternatively a direct pressure may be applied.
- the manifold structure 412 may behave anisotropically.
- the longitudinal members 456 may move laterally towards each other. Each longitudinal member 456 move closer to an adjacent longitudinal member 456 than the adjacent longitudinal members 456 were prior to the introduction of the reduced pressure.
- the manifold structure 412 does not substantially contract in a direction substantially parallel to the longitudinal members 456 .
- the manifold structure 412 may deform more in a direction substantially perpendicular to the longitudinal members 456 (as illustrated by arrows 458 in FIG. 5A ) without a proportional deformation in the direction parallel with the longitudinal members 456 .
- the deformation is typically within the same plane. This may be advantageous if the system employs other components, such as an anisotropic drape or another manifold, for drawing the wound together during reduced pressure therapy wherein the illustrative manifold structure 412 contracts in a manner complimentary therewith. If spaced lateral connecting members 460 are used in sufficient number, very little contraction may take place.
- the manifold structure 412 is configured such that some longitudinal members 456 are arranged substantially perpendicular to other longitudinal members 456 whereby the manifold structure 412 partially contracts, or contracts in a more limited manner, in two directions within the same plane when subjected to a reduced pressure.
- FIGS. 6A and 6B another illustrative, non-limiting embodiment of a microstrain-inducing manifold 512 for use with a reduced-pressure wound treatment system, such as a reduced-pressure wound treatment system 100 ( FIG. 1 ), is shown.
- the microstrain-inducing manifold 512 includes a mat 558 , or base, from which a plurality of shaped projections 526 extend.
- the mat 558 has a first side 513 and a second, patient-facing side 515 .
- the shaped projections 526 are tapered and in particular are substantially conical in shape, but it will be appreciated that the projections 526 may have any suitable shape capable of creating microstrain within the wound.
- the projections 526 may extend from the mat 558 at any suitable angle.
- the projections 526 have substantially equal heights, but the mat 558 may include projections 526 of varying heights. Portions of the mat 558 may not have any projections such that microstrain is not provided to certain areas within the wound. Additionally, the stiffness of the shaped projections 526 and pitch of the shaped projections 526 may vary along the mat 558 such that the microstrain created by the projections 526 may be greater in certain areas of the wound versus other areas.
- the shaped projections 526 may be formed as integral portions of the mat 558 or coupled to the mat 558 by any suitable techniques, including but not limited to mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc.
- the mat 558 may also includes a plurality of apertures 560 ( FIG. 6B ) disposed between the projections 526 to improve the distribution of fluids provided to and removed from the area of tissue around the microstrain-inducing manifold 512 .
- the shaped projections 526 may be formed from a modified honey on the mat 558 .
- the honey may be modified so that it is solid or partially solid and retains its shape for at least a certain amount of time whilst engaging the wound.
- the honey may act as an antimicrobial agent and may be absorbed by the patient after a period of time. Other dissolvable substances may be used as well.
- the microstrain-inducing manifold 512 is typically placed proximate the tissue site with the second, patient-facing side 515 facing the patient and covered with a sealing member. Reduced pressure is then delivered to the microstrain-inducing manifold 512 . When subjected to a reduced pressure, the microstrain-inducing manifold 512 impinges on the wound whereby the shaped projections 526 create microstrain within the wound. Additionally, exudate and other fluids pass through the mat 558 via the apertures 560 . Also, in some instances, it may be desirable to avoid increasing microstrain within the wound via the shaped projections 526 .
- the microstrain-inducing manifold 512 may be inverted such that the first side 513 of the mat 558 is placed against the wound and the shaped projections 526 extend towards the sealing member (not shown).
- the microstrain-inducing manifold 512 may assist in perfusion and fluid removal (via the apertures 560 ) without also increasing microstrain within the wound via the shaped projections 526 .
- a microstrain-inducing manifold member 624 for use with a reduced-pressure wound treatment system such as the reduced-pressure wound treatment system 100 in FIG. 1 , is shown.
- a microstrain-inducing manifold may be formed by a plurality of microstrain-inducing manifolds 624 .
- Each microstrain-inducing manifold member 624 has one or more shaped projections 626 extending from a surface 631 .
- the microstrain-inducing manifold members 624 are not interconnected by a network of connecting members.
- a plurality of microstrain-inducing manifold members 624 may be poured into a wound whereby they work together to form the microstrain-inducing manifold in the wound (in situ) and whereby the shaped projections 626 of the microstrain-inducing manifold members 624 contact the wound to create microstrain therein.
- the plurality of microstrain-inducing manifold members 624 may fill the entire wound.
- the plurality of microstrain-inducing manifold members 624 may partially fill the wound, and, optionally, an alternative manifold may be placed atop the microstrain-inducing manifold members 624 to fill the wound.
- the microstrain-inducing manifold members 624 may have a coating of material that allows the microstrain-inducing manifold members 624 to fuse or sinter in situ to one another and form a single, integral manifold.
- coatings include the following: any water soluble, swellable, or softenable material, including polymers such as poly vinyl alcohol and its copolymer, polyvinyl pyrrolidone and its copolymers, polyethylene oxide and its copolymers, polypropylene oxide and its copolymers, hydroxyl, carboxyl, and sulphonyl containing polymers (e.g., hydroxyl ethyl acrylate, carboxyl methyl cellulose, acrylamido methyl propane sulphonic acid and its salts), alginates, gums (e.g. xanthan and guar), other hydrogels and hydrocolloids.
- polymers such as poly vinyl alcohol and its copolymer, polyvinyl pyrroli
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Rehabilitation Therapy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Surgical Instruments (AREA)
Abstract
Microstrain-inducing manifolds, systems, and methods are presented that involve microstrain-inducing manifolds that include a plurality of shaped projections for creating microstrain. The shaped projections may be tapered projections. A system may include a sealing member for placing over the tissue site, a microstrain-inducing manifold, and a reduced-pressure subsystem that delivers reduced pressure to the sealing member. The reduced pressure causes the shaped projections to create microstrain at the tissue site. Other methods, apparatuses, and systems are also presented.
Description
- This application is a continuation of U.S. patent application Ser. No. 15/448,793, entitled “Reduced-Pressure Wound Treatment Systems and Methods Employing Microstrain-Inducing Manifolds,” filed Mar. 3, 2017, which is a continuation of U.S. patent application Ser. No. 13/963,809, entitled “Reduced-Pressure Wound Treatment Systems and Methods Employing a Microstrain-Inducing Manifold,” filed Aug. 9, 2013, which is a continuation of U.S. patent application Ser. No. 12/639,253, now U.S. Pat. No. 9,622,915, entitled “Reduced-Pressure Wound Treatment Systems and Methods Employing a Microstrain-Inducing Manifold,” filed Dec. 16, 2009, now U.S. Pat. No. 8,529,528, which claims the benefit, under 35 U.S.C. § 119(e), of the filing of U.S. Provisional Patent Application No. 61/140,662, entitled “Reduced-Pressure Wound Treatment Systems and Methods Employing a Microstrain-Inducing Manifold,” filed Dec. 24, 2008, which is incorporated herein by reference for all purposes. U.S. patent application Ser. No. 12/639,253, filed Dec. 12, 2009, now U.S. Pat. No. 8,529,528, is a previous co-pending application of U.S. patent application Ser. No. 12/639,288, filed Dec. 16, 2009, now U.S. Pat. No. 8,708,984, entitled, “Reduced-Pressure Wound Treatment Systems and Methods Employing Manifold Structures.”
- The present invention relates generally to medical treatment systems and, more particularly, to reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds.
- Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “NPWT,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, which may include faster healing and increased formulation of granulation tissue.
- Negative pressure therapy, or reduced-pressure therapy, has been used to promote healing across a wide range of wound types. Typically, an open-cell foam is placed directly into the wound bed. A drape is then used to cover the dressing and seal the wound. The sealing member is then fluidly coupled to a reduced-pressure therapy unit to provide negative pressure, or reduced pressure, to the wound through the foam. While this approach has produced meaningful results, shortcomings and areas of desired of improvement remain.
- Shortcomings with wound care systems and methods are addressed by the illustrative embodiments herein. According to one illustrative embodiment, a reduced-pressure wound treatment system for treating tissue on a patient includes a microstrain-inducing manifold for disposing proximate the tissue that includes a plurality of shaped projections for creating microstrain within the tissue, a sealing member for placing over the tissue and microstrain-inducing manifold and operable to form a fluid seal over the tissue and microstrain-inducing manifold, and a reduced-pressure subsystem for delivering a reduced pressure to the sealing member. The shaped projections comprise tapered projections.
- According to another illustrative embodiment, a microstrain-inducing manifold for treating tissue on a patient includes a plurality of shaped projections for creating microstrain within the tissue. The shaped projections comprise tapered projections.
- According to another illustrative embodiment, a reduced-pressure wound treatment system for treating tissue on a patient includes a microstrain-inducing manifold for disposing proximate the tissue. The microstrain-inducing manifold includes a plurality of interconnected nodes. At least one of the interconnected nodes includes at least one shaped projection for creating microstrain within the tissue. The shaped projection may be an angled projection. The system further includes a sealing member for placing over the tissue and manifold. The sealing member is operable to form a fluid seal over the tissue and microstrain-inducing manifold. The system further includes a reduced-pressure subsystem for delivering a reduced pressure to the sealing member.
- According to another illustrative embodiment, a microstrain-inducing manifold for treating tissue on a patient includes a plurality of interconnected nodes. At least one of the interconnected nodes includes at least one shaped projection for creating microstrain within the tissue. The shaped projection may be an angled projection.
- According to another illustrative embodiment, a method for treating tissue on a patient includes placing a microstrain-inducing manifold proximate the tissue of the patient. The microstrain-inducing manifold includes a plurality of shaped projections for creating microstrain within the tissue. The shaped projections may be tapered projections. The method further includes disposing a sealing member over the microstrain-inducing manifold and the patient's epidermis; forming a fluid seal between the sealing member and the patient's epidermis; and providing reduced pressure to the microstrain-inducing manifold whereby the plurality of shaped projections create microstrain within the tissue.
- Other features and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
- A more complete understanding of the present invention may be obtained by reference to the following Detailed Description when taken in conjunction with the accompanying Drawings wherein:
-
FIG. 1 is a schematic, perspective view of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system for treating a wound on a patient shown over a wound; -
FIG. 2 is a schematic, cross-sectional view of a portion of the system ofFIG. 1 taken along line 2-2 inFIG. 1 ; -
FIG. 3A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a tissue site, such as a wound, on a patient as part of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system; -
FIG. 3B is an enlarged detail of the perspective view ofFIG. 3A ; -
FIG. 3C is a side view of a portion of an interconnected node and shaped projection of the microstrain-inducing manifold shown inFIGS. 3A and 3B ; -
FIG. 4A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a tissue site; -
FIG. 4B is a schematic, top view of the microstrain-inducing manifold ofFIG. 4A ; -
FIG. 5A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a wound on a patient; -
FIG. 5B is an enlarged partial view of the microstrain-inducing manifold ofFIG. 5A ; -
FIG. 6A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a wound on a patient as part of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system; -
FIG. 6B is an enlarged partial view of the microstrain-inducing manifold ofFIG. 6A ; and -
FIG. 7 is a schematic, side view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold. - In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown, by way of illustration, specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the invention, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims.
- Referring now primarily to
FIGS. 1-3B , an illustrative, non-limiting embodiment of a reduced-pressurewound treatment system 100 for treating atissue site 103 on a patient is presented. Thetissue site 103 may be, for example, awound 102, or damaged area of tissue, on a patient. Thetissue site 103 may be the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue. Unless otherwise indicated, as used herein, “or” does not require mutual exclusivity. While the reduced-pressurewound treatment system 100 is shown in the context of thewound 102, it will be appreciated that the reduced-pressurewound treatment system 100 may be used to treat many different types oftissue sites 103 and wounds including area wounds, incisions, internal wounds, or other tissue sites. The reduced-pressurewound treatment system 100 is shown on thewound 102, which is through theepidermis 104, or generally skin, and thedermis 106 and reaching into a hypodermis, orsubcutaneous tissue 108. - The reduced-pressure
wound treatment system 100 generally includes a sealingmember 110, a microstrain-inducingmanifold 112, and a reduced-pressure subsystem 114. As will be described further below, in operation the microstrain-inducingmanifold 112 induces microstrain and may be referred to as a microstrain-inducing manifold. The microstrain-inducingmanifold 112 has afirst side 113 and a second, patient-facingside 115. - Among the numerous benefits of the reduced-pressure
wound treatment system 100 is the biological response initiated by microstrain within thewound 102. Microstrain results from pressure distributed with the microstrain-inducingmanifold 112 to atissue site 103, such as awound surface 105 of thewound 102. It is believed that this action creates areas of cell surface strain, or microdeformation. The cells appear to respond to the strain by expressing special receptors on the surface of the cells and turning on genetic pathways in the cells, which promote healing activities. The healing activities may include increased metabolic activity, stimulation of fibroblast migration, increased cellular proliferation, extra cellular matrix production, and the formation of granulation tissue, as well as a decrease in edema and a subsequent improvement of perfusion at thetissue site 103. With respect to thewound 102, over time, granulation tissue fills thewound 102 and thereby further reduces volume and prepares thewound 102 for final closure by secondary or delayed primary intention. - The sealing
member 110 is generally formed from a flexible sheet. The sealingmember 110 includes afirst surface 120 and a patient-facingsurface 122. The sealingmember 110 may be sized so that the sealingmember 110 overlaps thewound 102 in such a manner that adrape extension 116 extends beyond the peripheral edge of thewound 102. - The sealing
member 110 may be formed from any material that provides a fluid seal. As used herein, “fluid seal,” or “seal,” means a seal adequate to maintain reduced pressure at a desired site, e.g., a tissue site, given the particular reduced-pressure source involved. The sealing member may, for example, be an impermeable or semi-permeable, elastomeric material. “Elastomeric” means having the properties of an elastomer. Elastomeric generally refers to a polymeric material that has rubber-like properties. More specifically, most elastomers have ultimate elongations greater than 100% and a significant amount of resilience. The resilience of a material refers to the material's ability to recover from an elastic deformation. Examples of elastomers may include, but are not limited to, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones. Specific examples of sealing member materials include a silicone drape, 3M Tegaderm® drape, acrylic drape such as one available from Avery Dennison, or an incise drape. - An
attachment member 118 or device may be coupled to the sealingmember 110. Theattachment member 118 is operable to removably couple the sealingmember 110 to a patient'sepidermis 104. As used herein, the term “coupled” includes coupling via a separate object and includes direct coupling. The term “coupled” also encompasses two or more components that are continuous with one another by virtue of each of the components being formed from the same piece of material. Also, the term “coupled” may include chemical, such as via a chemical bond, mechanical, thermal, or electrical coupling. Fluid coupling means that fluid is in communication between the designated parts or locations. The sealingmember 110 andattachment member 118 work together to form a fluid seal over the patient'sepidermis 104. Theattachment member 118 may be any material suitable to help couple the sealingmember 110 to a patient'sepidermis 104. For example, theattachment member 118 may be a pressure-sensitive adhesive, heat-activated adhesive, sealing tape, double-sided sealing tape, paste, hydrocolloid, hydrogel, hooks, sutures, etc. - In the illustrative embodiment, the
attachment member 118 is anadhesive layer 119 coupled to the patient-facingsurface 122 of thedrape extension 116. Theattachment member 118 may span the entire width or a portion of the patient-facingsurface 122 of the sealingmember 110. Alternatively, in the case of sealing tape, theattachment member 118 may be applied over the entirefirst surface 120 of the sealingmember 110, or over the first surface of thedrape extensions 116. - The microstrain-inducing
manifold 112 is typically positioned between the second, patient-facingsurface 122 of the sealingmember 110 and thetissue site 103, e.g., thewound 102. The microstrain-inducingmanifold 112 may be sized to approximate the estimated area of thewound 102, although a larger or smaller size may be used in different applications. In the illustrative embodiment, the microstrain-inducingmanifold 112 includes a plurality ofinterconnected nodes 124. Theinterconnected nodes 124 may have a substantially circular cross-section, but it will be appreciated that theinterconnected nodes 124 may have any suitable cross-section including, but not limited to, triangular, square, rectangular, hexagonal, octagonal, elliptical, etc. - Each
interconnected node 124 may include one or moreshaped projections 126. The shapedprojections 126 are operable to create microstrain at the cellular level within thetissue site 103, e.g., thewound 102. While the illustrative embodiment shows eachinterconnected node 124 having a plurality of shapedprojections 126, it will be appreciated that someinterconnected nodes 124 may be formed to avoid creating microstrains in certain areas. For example, one or moreshaped projections 126 may be formed with a lower profile in a certain area or be absent all together in certain areas. Moreover, an additional manifold with no shaped projections, e.g., a smooth, laminar manifold, may be placed between at least a portion of the shapedprojections 126 of the microstrain-inducingmanifold 112 and a portion of thetissue site 103 to prevent the creation of strain in a certain area. It is believed that avoiding microstrains in certain areas is helpful to overall patient care. For example, it may be desirable to have a microstrain-inducingmanifold 112 withoutprojections 126 or that does not create microstrains in certain areas if a portion of the microstrain-inducingmanifold 112 will lay on top of a vein, an artery, graft(s), objects used for adjunctive treatment or therapy (e.g., stents), exposed organs (e.g., heart or bowel), etc. - The shaped
projections 126 may be substantially the same size. Alternatively, someprojections 126 may be larger or smaller than others. In one alternative, some shapedprojections 126 may have a larger pitch than others, where “pitch” is defined by theangle 128 between areference line 127 formed to have a right angle with alongitudinal axis 129 of the shapedprojection 126 as shown in cross section inFIG. 3C . Each shapedprojection 126 has anouter surface 130 and abase 132. While the shapedprojections 126 in the illustrative embodiment are conical in shape, it will be appreciated that the shapedprojections 126 may have any suitable shape capable of creating a microstrain within thewound 102; for example, the shapedprojections 126 may be substantially cube shaped, pyramid shaped, hemispherically shaped, cylindrically shaped, triangularly shaped, cylindrically shaped with a distal recess, tapered, more elaborately shaped, etc. The shapedprojections 126 are typically angled or tapered from a thick proximal end to a thin distal end or vice versa. In one embodiment, the shapedprojections 126 are formed of the same material as theinterconnected nodes 124. Alternatively, at least some of the shapedprojections 126 may be formed from a different material or the same material type of material with different properties than theinterconnected nodes 124 or the other shapedprojections 126. Via material selection, one may control the stiffness of theinterconnected nodes 124 such that greater microstrain may be provided in certain areas of thewound 102 versus others. Theinterconnected nodes 124, shapedprojections 126, and the microstrain-inducingmanifold 112 generally may be formed of a foam material or a non-foam material. - The
interconnected nodes 124 may be interconnected using a network of connectingmembers 134. For example, the network of connectingmembers 134 may include a plurality ofmembers 136 with eachmember 136 coupling adjacentinterconnected nodes 124 to one another. In the illustrative embodiment, themembers 136 have a substantially circular cross-section; however, it will be appreciated that themembers 136 may have any suitable cross-section, including, but not limited to, triangular, square, rectangular, hexagonal, octagonal, elliptical, etc. In addition, as will be discussed below, the connectingmembers 134 may be configured such that the microstrain-inducingmanifold 112 behaves anisotropically when subjected to a reduced pressure. - The
interconnected nodes 124, connectingmembers 134, and shapedprojections 126 are arranged such that the microstrain-inducingmanifold 112 includes a plurality of flow channels 140 (FIG. 3B ) or pathways between theinterconnected nodes 124. Theflow channels 140 improve distribution of fluids provided to and removed from the area of tissue around the microstrain-inducingmanifold 112. Thus, the microstrain-inducingmanifold 112 is operable to assist in applying reduced pressure to, delivering fluids to, or removing fluids from atissue site 103. Moreover, the design of microstrain-inducingmanifold 112 helps to avoid painful removal caused by in-growth, i.e., when growth of granulation tissue occurs into a manifold, and allows for easier removal from thetissue site 103. - The microstrain-inducing
manifold 112 may be formed from any suitable material. By way of example only, and without limitation, the microstrain-inducingmanifold 112 may be formed from an elastomer, a bioabsorbable/biodegradable polymer, etc. In addition, the manifold material may itself be, or may be combined with, a radio opaque material or a UV florescent material such that thewound 102 may be scanned with an X-ray or UV light in order to determine whether or not any remnants of the microstrain-inducingmanifold 112 remain in thewound 102 after efforts have been made to remove the microstrain-inducingmanifold 112 from thewound 102. Additionally, the shapedprojections 126, or microstrain-inducingmanifold 112 as a whole, may be coated with a drug (e.g., an anticoagulant), an antimicrobial agent (e.g., silver or copper), a hydrophilic material, etc. Optionally, the microstrain-inducingmanifold 112 may also be formed with additional components, e.g., a delivery tube (not shown), whereby drugs or antimicrobial agents may be delivered to thewound 102 through the microstrain-inducingmanifold 112. - The microstrain-inducing
manifold 112 may be formed by any suitable process, including, but not limited to, micromolding, injection molding, casting, etc. The shapedprojections 126 may be formed to be substantially integral with correspondinginterconnected nodes 124 or may be coupled to correspondinginterconnected nodes 124 by any suitable technique, including, but not limited to, mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc. - The microstrain-inducing
manifold 112 may include numerous devices for creating point pressure or otherwise inducing microstrain. In one illustrative, non-limiting embodiment, the microstrain-inducingmanifold 112 includes limited contact points with thetissue site 103. The contact points contribute to the inducement of microstrain at thetissue site 103. Thus, in one illustrative, non-limiting embodiment, the microstrain-inducingmanifold 112 adjacent thetissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducingmanifold 112 directly impinging on thetissue site 103 may be less than 40 percent of the surface area X (40% X). As used herein, “projection surface area” means the area that a general projection of an item would make on a flat surface. - In another illustrative, non-limiting embodiment, the microstrain-inducing
manifold 112 adjacent thetissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducingmanifold 112 directly impinging on thetissue site 103 may be less than 30 percent of the surface area X (30% X). In another illustrative, non-limiting embodiment, the microstrain-inducingmanifold 112 adjacent thetissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducingmanifold 112 directly impinging on thetissue site 103 may be less than 20 percent of the surface area X (20% X). In one illustrative, non-limiting embodiment, the microstrain-inducingmanifold 112 adjacent thetissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducingmanifold 112 directly impinging on thetissue site 103 may be less than 10 percent of the surface area X (10% X). In one illustrative, non-limiting embodiment, the microstrain-inducingmanifold 112 adjacent thetissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducingmanifold 112 directly impinging on thetissue site 103 may be less than 5 percent of the surface area X (5% X). - In still another illustrative, non-limiting embodiment, the microstrain-inducing
manifold 112 adjacent thetissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducingmanifold 112 directly impinging on thetissue site 103 may be less than 2 percent of the surface area X (2% X). In one illustrative, non-limiting embodiment, the microstrain-inducingmanifold 112 adjacent thetissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducingmanifold 112 directly impinging on thetissue site 103 may be less than 1 percent of the surface area X (1% X). In one illustrative, non-limiting embodiment, the microstrain-inducingmanifold 112 adjacent thetissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducingmanifold 112 directly impinging on thetissue site 103 may be less than 0.5 percent of the surface area X (0.5% X). - In one illustrative, non-limiting embodiment, the microstrain-inducing
manifold 112 adjacent thetissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducingmanifold 112 directly impinging on thetissue site 103 may be less than 0.2 percent of the surface area X (0.2% X). Referring toFIG. 2 , the microstrain-inducingmanifold 112 adjacent totissue site 103 103, e.g., woundsurface 105, may cover thewound surface 105, and may have a projection surface area X, and yet the portion of microstrain-inducingmanifold 112 directly impinging on thewound surface 105 may only be 0.2 percent of X. Referring toFIG. 3C , it should be understood that the impinging portion may only be a portion of anouter surface 130 of each of the plurality of shapedprojections 126. - The microstrain-inducing
manifold 112 may be disposed proximate thewound 102 such that theinterconnected nodes 124 engage thewound surface 105. In one illustrative embodiment, the microstrain-inducingmanifolds 112 are stacked on top of one another to substantially fill thewound 102. However, it will be appreciated that a single microstrain-inducingmanifold 112 may be employed or a multi-layer microstrain-inducing manifold may also be formed and used. The microstrain-inducingmanifold 112 may be formed from a singleinterconnected node 124 with a shapedprojection 126; multiple independentinterconnected nodes 124 with shapedprojections 126; or a group ofinterconnected nodes 124, which include shapedprojections 126, that are interconnected with the connectingmembers 134. - It will also be appreciated that a single microstrain-inducing
manifold 112 may be rolled up or folded over itself in order to fill thewound 102. Furthermore, it will be appreciated that a single microstrain-inducingmanifold 112 may be loaded into thewound 102 and an additional manifold placed atop themanifold 112. Examples of additional manifolds that may be placed atop the microstrain-inducingmanifold 112 include, without limitation, devices that have structural elements arranged to form flow channels, cellular foam such as open-cell foam, porous tissue collections, and liquids, gels and foams that include or cure to include flow channels. - Referring again to
FIG. 1 , the reduced-pressure subsystem 114 includes a reduced-pressure source 142, which may take many different forms. The reduced-pressure source 142 provides reduced pressure as a part of the reduced-pressurewound treatment system 100. As used herein, “reduced pressure” generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure at the tissue site. Reduced pressure may initially generate fluid flow in the microstrain-inducingmanifold 112, aconduit 150, and proximate thetissue site 103. As the hydrostatic pressure around thetissue site 103 approaches the desired reduced pressure, the flow may subside, and the reduced pressure may be maintained. Unless otherwise indicated, values of pressure stated herein are gauge pressures. The reduced pressure delivered may be static or dynamic (patterned or random) and may be delivered continuously or intermittently. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site may be more than the pressure normally associated with a complete vacuum. Consistent with the use herein, an increase in reduced pressure or vacuum pressure typically refers to a relative reduction in absolute pressure. - The reduced-
pressure subsystem 114 provides reduced pressure. The reduced-pressure subsystem 114 includes a reduced-pressure source 142 that may be any source of a reduced pressure, such a vacuum pump, wall suction, etc. While the amount and nature of reduced pressure applied to a tissue site will typically vary according to the application, the reduced pressure will typically be between −5 mm Hg and −500 mm Hg. Pressure may be applied to the microstrain-inducingmanifold 112 in other ways as well; for example, a pressure wrap may be used. - In the illustrative embodiment of
FIG. 1 , the reduced-pressure source 142 is shown having abattery compartment 144 and acanister region 146 withwindows 148 providing a visual indication of the level of fluid withincanister 146. An interposed membrane filter, such as hydrophobic or oleophobic filter, may be interspersed between theconduit 150, or tubing, and the reduced-pressure source 142. - The reduced pressure supplied by the reduced-
pressure source 142 is delivered through theconduit 150 to a reduced-pressure interface 152, which may be anelbow port 154. In one illustrative embodiment, theport 154 is a TRAC® technology port available from Kinetic Concepts, Inc. of San Antonio, Texas. The reduced-pressure interface 152 allows the reduced pressure to be delivered to the sealingmember 110 and realized within an interior portion of sealingmember 110 as well as the microstrain-inducingmanifold 112. In this illustrative embodiment, theport 154 extends through the sealingmember 110 to the microstrain-inducingmanifold 112. - In use, the reduced-pressure
wound treatment system 100 may be applied to a patient'sepidermis 104 over thetissue site 103, e.g., wound 102. The microstrain-inducingmanifold 112 may be disposed proximate thetissue site 103, e.g., disposed within thewound 102, or may overlay a portion of thewound 102. The sealingmember 110 may be placed over the top of the microstrain-inducingmanifold 112 such thatdrape extensions 116 extend beyond the periphery of thewound 102. Thedrape extensions 116 are secured to the patient's epidermis 104 (or a gasket member, such an additional piece of over drape surrounding the wound edges) by theattachment member 118 in order to form a fluid seal over thewound 102. As used herein, reference to forming a fluid seal with the patient's epidermis shall be deemed to also include forming a seal with a gasket proximate thewound 102. - The reduced-
pressure interface 152 is applied, if not already installed, and theconduit 150 fluidly coupled at one end to the reduced-pressure interface 152. The other end of theconduit 150 is fluidly coupled to the reduced-pressure source 142. The reduced-pressure source 142 may be activated such that reduced pressure is delivered to the sealingmember 110 and microstrain-inducingmanifold 112. The reduced pressure provides reduced-pressure treatment to thetissue site 103, removes fluids, and may force the shapedprojections 126 of the microstrain-inducingmanifold 112 against thewound 102 such that they create a microstrain at the cellular level within thewound 102. As previously suggested, the microstrain may promote cellular proliferation, formation of granular tissue, and other beneficial effects. Alternatively, the microstrain-inducingmanifold 112 may be placed proximate thetissue site 103 and then pressure may be applied by using a wrap over the microstrain-inducingmanifold 112 or other source of pressure. - Referring now primarily to
FIGS. 4A and 4B , an illustrative, non-limiting embodiment of a microstrain-inducingmanifold 212 for use as part of a reduced-pressure wound treatment, such as the reduced-pressurewound treatment system 100 inFIG. 1 , is shown. The microstrain-inducingmanifold 212 includesinterconnected nodes 224, which include shapedprojections 226 extending from theinterconnected nodes 224. In the illustrative embodiment, the shapedprojections 226 are conical in shape; however, it will be appreciated that the shapedprojections 226 may be any suitable shape capable of creating microstrain within a wound as previously discussed. Moreover, while eachinterconnected node 224 of the illustrative embodiment includes two projections 226 (one directed up and one directed down for the orientation shown inFIG. 4A ), it will be appreciated that any number ofprojections 224 may extend from eachinterconnected node 224 or that some of theinterconnected nodes 224 may have noprojections 224. Also, in the illustrative embodiment, eachprojection 226 extends substantially normal from a correspondinginterconnected node 224, but it will be appreciated that eachprojection 226 may extend from the correspondinginterconnected node 224 at any angle. - The
interconnected nodes 224 are spaced apart and interconnected by a network of connectingmembers 234 as clearly shown inFIG. 4B . The network of connectingmembers 234 includes a plurality ofcurved members 236. A plurality offlow channels 240 are formed between theinterconnected nodes 224 andmembers 236. Themembers 236 havecurved surfaces 290 that are curved in a cooperative manner with one another or with the radius of one or more correspondinginterconnected nodes 224 such that when the microstrain-inducingmanifold 212 is subjected to a reduced pressure, the microstrain-inducingmanifold 212 collapses (partially or fully) in two directions (e.g., along thex-axis 286 and y-axis 288) but not at all or to a lesser extent in a third direction (e.g., the z-axis 284). As the microstrain-inducingmanifold 212 collapses, eachcurved surface 290 of eachmember 236 abuts or approaches acurved surface 290 of anadjacent member 236 or at least one correspondinginterconnected node 224. This may be particularly advantageous if the reduced-pressure wound treatment system is configured to assist in drawing the wound together during reduced pressure therapy. - Referring now primarily to
FIGS. 5A and 5B , an illustrative, non-limiting embodiment of amanifold structure 412, which is a form of a microstrain-inducing manifold, is presented. Themanifold structure 412 is for use with a reduced-pressure wound treatment system, such as the reduced-pressurewound treatment system 100 ofFIG. 1 , is shown. Themanifold structure 412 includes one or morelongitudinal members 456. Thelongitudinal members 456 may be coupled in a spaced relationship bylateral connecting members 460. Thelateral connecting members 460 may be coupled to thelongitudinal members 456. Thelongitudinal members 456 andlateral connecting members 460 are shown with circular cross-sections, but it should be appreciated that thelongitudinal members 456 andlateral connecting members 460 may have any suitable cross-sectional shape. While reference is made to longitudinal and lateral members, themembers - Each
longitudinal member 456 of themanifold structure 412 includes one or moreshaped projections 426 for creating a microstrain within a wound. Thelongitudinal members 456 and shapedprojections 426 are arranged such that themanifold structure 412 includes a plurality offlow channels 440 or pathways between adjacentlongitudinal members 456 or betweenprojections 426. Theflow channels 440 facilitate distribution of fluids provided to and removed from the area of tissue around themanifold structure 412. It should be understood that any combination oflongitudinal members 456 andlateral members 460 may be used. For example, themanifold structure 412 may be formed by a longitudinally connected group oflongitudinal members 456 withprojections 426. There are eight such longitudinal groups shown inFIG. 5A , and while shown with thelateral connecting members 460, thelateral connecting members 460 may be omitted in some embodiments. Moreover, while onlylateral connecting members 460 are shown on the ends, it should be understood that any number of permutations are possible, andlateral members 460 may be distributed at various locations between thelongitudinal members 456. - In the illustrative embodiment, each
shaped projection 426 projects substantially normal from the correspondinglongitudinal member 456. As used here, “normal” is a vector which perpendicular to that surface. For a non-flat surface, the normal vector may be taken at a point and is the same as a normal to the tangent plane at that point. It should be appreciated, however, that eachshaped projection 426 may project at any angle relative to the correspondinglongitudinal member 456. Each shapedprojection 426 may include acolumnar body 427, which has a first outer diameter (D1), and anenlarged member 429, which has a second outer diameter (D2). Eachenlarged member 429 is positioned at the distal end of an associatedcolumnar body 427. Eachcolumnar body 429 may have any shape, e.g., the cross-section may be a circular, square, elliptical, irregular, etc., and may vary along its longitudinal dimension. Theenlarged member 429 may be a spherical member as shown or may take any other shape, such as rounded cylindrical member, a cubical member, or an irregular shape. The second outer diameter (D2) of theenlarged member 429 is greater than the first outer diameter (D1) of thecolumnar body 427, i.e., D2>D1. In this regard, the shapedprojections 426 may be considered to be tapered from a larger distal end to a smaller proximal end. - Each shaped
projection 426 may have any suitable shape capable of creating a microstrain within the wound when the shapedprojection 426 impinges upon the wound. Additionally, in the illustrative embodiment, the shapedprojections 426 have substantially equal heights, but it will be appreciated that the shapedprojections 426 may have varying heights along eachlongitudinal member 456 or among the plurality oflongitudinal members 456. Also, it will be appreciated that certain portions of certainlongitudinal members 456 may not have shapedprojections 426 such that microstrain is not provided to certain areas within the wound. As with the microstrain-inducing manifolds previously discussed, themanifold structure 412 may be formed using any suitable process, including, but not limited to, micromolding, injection molding, casting, etc. The shapedprojections 426 may be formed to be substantially integral with correspondinglongitudinal members 456 or may be coupled to correspondinglongitudinal members 456 by any suitable technique including, but not limited to, mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc. - In use, the
manifold structure 412 is placed proximate the tissue site, e.g., wound, and a sealing member is deployed over themanifold structure 412 and tissue site. Reduced pressure may then be applied or alternatively a direct pressure may be applied. In some embodiments, e.g., embodiment with widely spacedlateral members 460, when themanifold structure 412 is subjected to a reduced pressure, themanifold structure 412 may behave anisotropically. In other words, when themanifold structure 412 is subjected to a reduced pressure, in addition to the shapedprojections 426 being forced into the wound to create microstrain, thelongitudinal members 456 may move laterally towards each other. Eachlongitudinal member 456 move closer to an adjacentlongitudinal member 456 than the adjacentlongitudinal members 456 were prior to the introduction of the reduced pressure. At the same time, themanifold structure 412 does not substantially contract in a direction substantially parallel to thelongitudinal members 456. - If the
lateral connecting members 460 are omitted, even further contraction may be possible. Themanifold structure 412 may deform more in a direction substantially perpendicular to the longitudinal members 456 (as illustrated byarrows 458 inFIG. 5A ) without a proportional deformation in the direction parallel with thelongitudinal members 456. The deformation is typically within the same plane. This may be advantageous if the system employs other components, such as an anisotropic drape or another manifold, for drawing the wound together during reduced pressure therapy wherein theillustrative manifold structure 412 contracts in a manner complimentary therewith. If spacedlateral connecting members 460 are used in sufficient number, very little contraction may take place. In an alternative embodiment, themanifold structure 412 is configured such that somelongitudinal members 456 are arranged substantially perpendicular to otherlongitudinal members 456 whereby themanifold structure 412 partially contracts, or contracts in a more limited manner, in two directions within the same plane when subjected to a reduced pressure. - Referring now primarily to
FIGS. 6A and 6B , another illustrative, non-limiting embodiment of a microstrain-inducingmanifold 512 for use with a reduced-pressure wound treatment system, such as a reduced-pressure wound treatment system 100 (FIG. 1 ), is shown. The microstrain-inducingmanifold 512 includes amat 558, or base, from which a plurality of shapedprojections 526 extend. Themat 558 has afirst side 513 and a second, patient-facingside 515. In the illustrative embodiment, the shapedprojections 526 are tapered and in particular are substantially conical in shape, but it will be appreciated that theprojections 526 may have any suitable shape capable of creating microstrain within the wound. Also, while the illustrative embodiment shows theprojections 526 extending substantially normal, i.e., perpendicular, from themat 558, it will be appreciated that theprojections 526 may extend from themat 558 at any suitable angle. Furthermore, in the illustrative embodiment, theprojections 526 have substantially equal heights, but themat 558 may includeprojections 526 of varying heights. Portions of themat 558 may not have any projections such that microstrain is not provided to certain areas within the wound. Additionally, the stiffness of the shapedprojections 526 and pitch of the shapedprojections 526 may vary along themat 558 such that the microstrain created by theprojections 526 may be greater in certain areas of the wound versus other areas. - The shaped
projections 526 may be formed as integral portions of themat 558 or coupled to themat 558 by any suitable techniques, including but not limited to mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc. Themat 558 may also includes a plurality of apertures 560 (FIG. 6B ) disposed between theprojections 526 to improve the distribution of fluids provided to and removed from the area of tissue around the microstrain-inducingmanifold 512. In an alternative embodiment, the shapedprojections 526 may be formed from a modified honey on themat 558. The honey may be modified so that it is solid or partially solid and retains its shape for at least a certain amount of time whilst engaging the wound. Advantageously, the honey may act as an antimicrobial agent and may be absorbed by the patient after a period of time. Other dissolvable substances may be used as well. - In operation, the microstrain-inducing
manifold 512 is typically placed proximate the tissue site with the second, patient-facingside 515 facing the patient and covered with a sealing member. Reduced pressure is then delivered to the microstrain-inducingmanifold 512. When subjected to a reduced pressure, the microstrain-inducingmanifold 512 impinges on the wound whereby the shapedprojections 526 create microstrain within the wound. Additionally, exudate and other fluids pass through themat 558 via theapertures 560. Also, in some instances, it may be desirable to avoid increasing microstrain within the wound via the shapedprojections 526. In such an instance, the microstrain-inducingmanifold 512 may be inverted such that thefirst side 513 of themat 558 is placed against the wound and the shapedprojections 526 extend towards the sealing member (not shown). Thus, the microstrain-inducingmanifold 512 may assist in perfusion and fluid removal (via the apertures 560) without also increasing microstrain within the wound via the shapedprojections 526. - Referring now primarily to
FIG. 7 , an illustrative, non-limiting embodiment of a microstrain-inducingmanifold member 624 for use with a reduced-pressure wound treatment system, such as the reduced-pressurewound treatment system 100 inFIG. 1 , is shown. A microstrain-inducing manifold may be formed by a plurality of microstrain-inducingmanifolds 624. Each microstrain-inducingmanifold member 624 has one or moreshaped projections 626 extending from asurface 631. Unlike the reduced-pressurewound treatment system 100 ofFIGS. 1-3B , the microstrain-inducingmanifold members 624 are not interconnected by a network of connecting members. Rather, a plurality of microstrain-inducingmanifold members 624 may be poured into a wound whereby they work together to form the microstrain-inducing manifold in the wound (in situ) and whereby the shapedprojections 626 of the microstrain-inducingmanifold members 624 contact the wound to create microstrain therein. The plurality of microstrain-inducingmanifold members 624 may fill the entire wound. Alternatively, the plurality of microstrain-inducingmanifold members 624 may partially fill the wound, and, optionally, an alternative manifold may be placed atop the microstrain-inducingmanifold members 624 to fill the wound. - In another alternative, the microstrain-inducing
manifold members 624 may have a coating of material that allows the microstrain-inducingmanifold members 624 to fuse or sinter in situ to one another and form a single, integral manifold. Non-limiting examples of coatings include the following: any water soluble, swellable, or softenable material, including polymers such as poly vinyl alcohol and its copolymer, polyvinyl pyrrolidone and its copolymers, polyethylene oxide and its copolymers, polypropylene oxide and its copolymers, hydroxyl, carboxyl, and sulphonyl containing polymers (e.g., hydroxyl ethyl acrylate, carboxyl methyl cellulose, acrylamido methyl propane sulphonic acid and its salts), alginates, gums (e.g. xanthan and guar), other hydrogels and hydrocolloids. - Although the present invention and its advantages have been disclosed in the context of certain illustrative, non-limiting embodiments, it should be understood that various changes, substitutions, permutations, and alterations can be made without departing from the scope of the invention as defined by the appended claims. It will be appreciated that any feature that is described in a connection to any one embodiment may also be applicable to any other embodiment.
Claims (20)
1. An apparatus for placement at a tissue site, comprising:
a plurality of nodes, each node having a substantially circular cross section;
a plurality of shaped projections, each shaped projection coupled to one of the plurality of nodes, each shaped projection comprising a conical shape; and
a plurality of connecting members, each connecting member coupled to at least one of the plurality of nodes at a first end of the connecting member, each connecting member coupled to at least one other node of the plurality of nodes at a second end of the connecting member, each connecting member comprising a substantially circular cross section.
2. The apparatus of claim 1 , wherein the apparatus is formed from an elastomer.
3. The apparatus of claim 1 , wherein the apparatus is formed from a bioabsorbable polymer.
4. The apparatus of claim 1 , wherein the apparatus is formed from a biodegradable polymer.
5. The apparatus of claim 1 , wherein the apparatus comprises a radio opaque material
6. The apparatus of claim 1 , wherein the apparatus comprises a UV fluorescent material.
7. The apparatus of claim 1 , wherein each of the plurality of nodes is substantially coplanar with an adjacent node.
8. The apparatus of claim 1 , wherein the plurality of shaped projections comprises a first plurality of shaped projections having a first pitch and a second plurality of shaped projections having a second pitch, each of the plurality of nodes having at least one shaped projection from the first plurality of shaped projections and one shaped projection from the second plurality of shaped projections.
9. The apparatus of claim 8 , wherein the first pitch is defined by an angle between a reference line formed to have a right angle with a longitudinal axis of the shaped projection and an outer surface of the shaped projection from the first plurality of shaped projections.
10. The apparatus of claim 8 , wherein the second pitch is defined by an angle between a reference line formed to have a right angle with a longitudinal axis of the shaped projection and an outer surface of the shaped projection from the second plurality of shaped projections.
11. A system for treating a tissue site, comprising:
a manifold configured to be placed at the tissue site, the manifold comprising:
a plurality of nodes, each node having a substantially circular cross section, a plurality of shaped projections, each shaped projection coupled to one of the plurality of nodes, each shaped projection comprising a conical shape, and
a plurality of connecting members, each connecting member coupled to at least one of the plurality of nodes at a first end of the connecting member, each connecting member coupled to at least one other node of the plurality of nodes at a second end of the connecting member, each connecting member comprising a substantially circular cross section;
a flexible sheet configured to be disposed over the manifold, the flexible sheet configured to form a fluid seal over the tissue site; and
a reduced-pressure source configured to be fluidly coupled to the tissue site through the flexible sheet.
12. The system of claim 11 , wherein the manifold is formed from an elastomer.
13. The system of claim 11 , wherein the manifold is formed from a bioabsorbable polymer.
14. The system of claim 11 , wherein the manifold is formed from a biodegradable polymer.
15. The system of claim 11 , wherein the manifold comprises a radio opaque material
16. The system of claim 11 , wherein the manifold comprises a UV fluorescent material.
17. The system of claim 11 , wherein each of the plurality of nodes is substantially coplanar with an adjacent node.
18. The system of claim 11 , wherein the plurality of shaped projections comprises a first plurality of shaped projections having a first pitch and a second plurality of shaped projections having a second pitch, each of the plurality of nodes having at least one shaped projection from the first plurality of shaped projections and one shaped projection from the second plurality of shaped projections.
19. The system of claim 18 , wherein the first pitch is defined by an angle between a reference line formed to have a right angle with a longitudinal axis of the shaped projection and an outer surface of the shaped projection from the first plurality of shaped projections.
20. The system of claim 18 , wherein the second pitch is defined by an angle between a reference line formed to have a right angle with a longitudinal axis of the shaped projection and an outer surface of the shaped projection from the second plurality of shaped projections.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/733,055 US20200147280A1 (en) | 2008-12-24 | 2020-01-02 | Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14066208P | 2008-12-24 | 2008-12-24 | |
US12/639,253 US8529528B2 (en) | 2008-12-24 | 2009-12-16 | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds |
US13/963,809 US9622915B2 (en) | 2008-12-24 | 2013-08-09 | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds |
US15/448,793 US10561768B2 (en) | 2008-12-24 | 2017-03-03 | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds |
US16/733,055 US20200147280A1 (en) | 2008-12-24 | 2020-01-02 | Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/448,793 Continuation US10561768B2 (en) | 2008-12-24 | 2017-03-03 | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200147280A1 true US20200147280A1 (en) | 2020-05-14 |
Family
ID=42267164
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/639,253 Active 2031-09-23 US8529528B2 (en) | 2008-12-24 | 2009-12-16 | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds |
US13/963,809 Active 2032-04-02 US9622915B2 (en) | 2008-12-24 | 2013-08-09 | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds |
US15/448,793 Active 2031-03-13 US10561768B2 (en) | 2008-12-24 | 2017-03-03 | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds |
US16/733,055 Abandoned US20200147280A1 (en) | 2008-12-24 | 2020-01-02 | Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/639,253 Active 2031-09-23 US8529528B2 (en) | 2008-12-24 | 2009-12-16 | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds |
US13/963,809 Active 2032-04-02 US9622915B2 (en) | 2008-12-24 | 2013-08-09 | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds |
US15/448,793 Active 2031-03-13 US10561768B2 (en) | 2008-12-24 | 2017-03-03 | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds |
Country Status (13)
Country | Link |
---|---|
US (4) | US8529528B2 (en) |
EP (3) | EP3669850A1 (en) |
JP (1) | JP5613173B2 (en) |
KR (1) | KR20110116140A (en) |
CN (1) | CN102264333B (en) |
AU (2) | AU2009330298B2 (en) |
BR (1) | BRPI0918310A2 (en) |
CA (1) | CA2745695C (en) |
MX (1) | MX2011006806A (en) |
RU (1) | RU2011122962A (en) |
SG (1) | SG172011A1 (en) |
TW (1) | TW201029697A (en) |
WO (1) | WO2010075179A2 (en) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9820888B2 (en) | 2006-09-26 | 2017-11-21 | Smith & Nephew, Inc. | Wound dressing |
GB0804654D0 (en) * | 2008-03-13 | 2008-04-16 | Smith & Nephew | Vacuum closure device |
CN102256638B (en) * | 2008-12-24 | 2014-04-23 | 凯希特许有限公司 | Membranes, systems, and methods for applying reduced pressure to a subcutaneous tissue site |
GB0902368D0 (en) | 2009-02-13 | 2009-04-01 | Smith & Nephew | Wound packing |
US8882730B2 (en) | 2010-03-12 | 2014-11-11 | Kci Licensing, Inc. | Radio opaque, reduced-pressure manifolds, systems, and methods |
US9358158B2 (en) * | 2010-03-16 | 2016-06-07 | Kci Licensing, Inc. | Patterned neo-epithelialization dressings, systems, and methods |
US9421132B2 (en) | 2011-02-04 | 2016-08-23 | University Of Massachusetts | Negative pressure wound closure device |
EP2670312B1 (en) | 2011-02-04 | 2020-11-18 | University of Massachusetts | Negative pressure wound closure device |
CN103619366B (en) | 2011-04-15 | 2018-02-16 | 马萨诸塞州大学 | Surgical cavity drainage and closed-system |
AU2012266095B2 (en) * | 2011-06-07 | 2016-05-05 | Smith & Nephew Plc | Wound contacting members and methods |
JP6224581B2 (en) * | 2011-06-24 | 2017-11-01 | ケーシーアイ ライセンシング インコーポレイテッド | Reduced pressure dressing with tissue fixation elements |
EP2782606B1 (en) | 2011-11-21 | 2021-01-20 | 3M Innovative Properties Company | Systems, devices, and methods for identifying portions of a wound filler left at a tissue site |
WO2013096091A1 (en) * | 2011-12-21 | 2013-06-27 | Kci Licensing, Inc. | A wound filler having dynamic motion |
EP2814556B1 (en) * | 2012-02-13 | 2016-12-07 | Integrated Healing Technologies | Wound dressing apparatus |
CA3122007A1 (en) | 2012-03-12 | 2013-09-19 | Smith & Nephew Plc | Reduced pressure apparatus and methods |
CA2874396A1 (en) | 2012-05-22 | 2014-01-23 | Smith & Nephew Plc | Wound closure device |
AU2013264938B2 (en) | 2012-05-22 | 2017-11-23 | Smith & Nephew Plc | Apparatuses and methods for wound therapy |
AU2013264937B2 (en) | 2012-05-24 | 2018-04-19 | Smith & Nephew Inc. | Devices and methods for treating and closing wounds with negative pressure |
RU2015104581A (en) | 2012-07-16 | 2016-09-10 | Смит Энд Нефью, Инк. | DEVICE FOR CLOSING THE Wound USING NEGATIVE PRESSURE |
WO2014024048A1 (en) * | 2012-08-08 | 2014-02-13 | Smith & Nephew Plc | Bespoke wound treatment apparatuses and methods for use in negative pressure wound therapy |
USD738487S1 (en) * | 2013-01-28 | 2015-09-08 | Molnlycke Health Care Ab | Suction device for negative pressure therapy |
RU2015142873A (en) | 2013-03-13 | 2017-04-19 | Смит Энд Нефью Инк. | DEVICE AND SYSTEMS FOR CLOSING A Wound USING NEGATIVE PRESSURE, AND METHODS FOR APPLICATION IN TREATING A WAN USING NEGATIVE PRESSURE |
WO2014140578A1 (en) | 2013-03-14 | 2014-09-18 | Smith & Nephew Plc | Compressible wound fillers and systems and methods of use in treating wounds with negative pressure |
JP6560201B2 (en) * | 2013-07-10 | 2019-08-14 | ケーシーアイ ライセンシング インコーポレイテッド | Manually regulated negative pressure pump with adapter for external pressure source |
CN105530898B (en) | 2013-07-16 | 2020-02-28 | 史密夫及内修公开有限公司 | Apparatus for wound therapy |
US10342891B2 (en) * | 2013-09-19 | 2019-07-09 | Medline Industries, Inc. | Wound dressing containing saccharide and collagen |
AU2014340232B2 (en) | 2013-10-21 | 2019-07-11 | Smith & Nephew Inc. | Negative pressure wound closure device |
US10201642B2 (en) | 2014-01-21 | 2019-02-12 | Smith & Nephew Plc | Collapsible dressing for negative pressure wound treatment |
US10179073B2 (en) | 2014-01-21 | 2019-01-15 | Smith & Nephew Plc | Wound treatment apparatuses |
JP2017512620A (en) * | 2014-03-28 | 2017-05-25 | スリーエム イノベイティブ プロパティズ カンパニー | Articles and methods for negative pressure wound closure therapy |
EP3797744A1 (en) | 2014-05-09 | 2021-03-31 | 3M Innovative Properties Company | Dressing with contracting layer for linear tissue sites |
AU2015255726B2 (en) | 2014-05-09 | 2020-03-05 | Solventum Intellectual Properties Company | Disruptive dressing for use with negative pressure and fluid instillation |
US10898217B2 (en) | 2014-05-09 | 2021-01-26 | Kci Licensing, Inc. | Dressing providing apertures with multiple orifice sizes for negative-pressure therapy |
WO2016174048A1 (en) | 2015-04-27 | 2016-11-03 | Smith & Nephew Plc | Reduced pressure apparatuses |
AU2016254119A1 (en) | 2015-04-29 | 2017-10-05 | Smith & Nephew Inc. | Negative pressure wound closure device |
US10064273B2 (en) | 2015-10-20 | 2018-08-28 | MR Label Company | Antimicrobial copper sheet overlays and related methods for making and using |
US10575991B2 (en) | 2015-12-15 | 2020-03-03 | University Of Massachusetts | Negative pressure wound closure devices and methods |
US10814049B2 (en) | 2015-12-15 | 2020-10-27 | University Of Massachusetts | Negative pressure wound closure devices and methods |
US11723809B2 (en) | 2016-03-07 | 2023-08-15 | Smith & Nephew Plc | Wound treatment apparatuses and methods with negative pressure source integrated into wound dressing |
CN109121396B (en) | 2016-04-26 | 2022-04-05 | 史密夫及内修公开有限公司 | Wound dressing and method for use with an integrated negative pressure source having a fluid intrusion inhibiting feature |
EP3452129B1 (en) | 2016-05-03 | 2022-03-23 | Smith & Nephew plc | Negative pressure wound therapy device activation and control |
US11305047B2 (en) | 2016-05-03 | 2022-04-19 | Smith & Nephew Plc | Systems and methods for driving negative pressure sources in negative pressure therapy systems |
WO2017191149A1 (en) | 2016-05-03 | 2017-11-09 | Smith & Nephew Plc | Optimizing power transfer to negative pressure sources in negative pressure therapy systems |
WO2018037075A1 (en) | 2016-08-25 | 2018-03-01 | Smith & Nephew Plc | Absorbent negative pressure wound therapy dressing |
WO2018041805A1 (en) | 2016-08-30 | 2018-03-08 | Smith & Nephew Plc | Systems for applying reduced pressure therapy |
WO2018060144A1 (en) | 2016-09-27 | 2018-04-05 | Smith & Nephew Plc | Wound closure devices with dissolvable portions |
WO2018060417A1 (en) | 2016-09-30 | 2018-04-05 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
JP2019532774A (en) | 2016-11-02 | 2019-11-14 | スミス アンド ネフュー インコーポレイテッド | Wound closure device |
AU2017375560B2 (en) | 2016-12-12 | 2023-07-06 | Smith & Nephew Plc | Pressure wound therapy status indication via external device |
CA3055664A1 (en) | 2017-03-08 | 2018-09-13 | Smith & Nephew Plc | Negative pressure wound therapy device control in presence of fault condition |
WO2018191274A1 (en) * | 2017-04-11 | 2018-10-18 | University Of Florida Research Foundation | Systems and methods for in-situ, bottom-up tissue generation |
WO2018206420A1 (en) | 2017-05-09 | 2018-11-15 | Smith & Nephew Plc | Redundant controls for negative pressure wound therapy systems |
AU201716716S (en) | 2017-05-11 | 2017-11-21 | MAƒA¶LNLYCKE HEALTH CARE AB | Wound dressings |
WO2018229009A1 (en) | 2017-06-13 | 2018-12-20 | Smith & Nephew Plc | Wound closure device and method of use |
US11324876B2 (en) | 2017-06-13 | 2022-05-10 | Smith & Nephew Plc | Collapsible structure and method of use |
EP3638174A1 (en) | 2017-06-14 | 2020-04-22 | Smith & Nephew plc | Collapsible sheet for wound closure and method of use |
US11123476B2 (en) | 2017-06-14 | 2021-09-21 | Smith & Nephew, Inc. | Fluid removal management and control of wound closure in wound therapy |
EP3638170B1 (en) | 2017-06-14 | 2024-03-13 | Smith & Nephew PLC | Collapsible structure for wound closure and method of use |
EP3638173A1 (en) | 2017-06-14 | 2020-04-22 | Smith & Nephew, Inc | Control of wound closure and fluid removal management in wound therapy |
US10751212B2 (en) * | 2017-06-26 | 2020-08-25 | Maryam Raza | Multilayer dressing device and method for preventing and treating pressure ulcers and chronic wounds |
WO2019020544A1 (en) | 2017-07-27 | 2019-01-31 | Smith & Nephew Plc | Customizable wound closure device and method of use |
WO2019030136A1 (en) | 2017-08-07 | 2019-02-14 | Smith & Nephew Plc | Wound closure device with protective layer and method of use |
US11375923B2 (en) | 2017-08-29 | 2022-07-05 | Smith & Nephew Plc | Systems and methods for monitoring wound closure |
WO2019053101A1 (en) | 2017-09-13 | 2019-03-21 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
GB201718070D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
GB201718072D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
EP3703632B1 (en) | 2017-11-01 | 2024-04-03 | Smith & Nephew plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
GB201718054D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Sterilization of integrated negative pressure wound treatment apparatuses and sterilization methods |
US11511032B2 (en) | 2018-03-12 | 2022-11-29 | Kci Licensing, Inc. | Dressing using differential surface features for use in compartment spaces |
CN112040915B (en) * | 2018-03-26 | 2022-04-01 | 帝皇工业有限公司 | Multi-lumen bridge for negative pressure wound therapy system |
WO2020005535A1 (en) * | 2018-06-28 | 2020-01-02 | Kci Licensing, Inc. | A highly conformable wound dressing |
US20200038283A1 (en) * | 2018-08-01 | 2020-02-06 | Kci Licensing, Inc. | Soft-Tissue Treatment With Negative Pressure |
USD898925S1 (en) | 2018-09-13 | 2020-10-13 | Smith & Nephew Plc | Medical dressing |
US20210338490A1 (en) * | 2018-10-17 | 2021-11-04 | Kci Licensing, Inc. | Systems, Apparatuses, And Methods For Negative-Pressure Treatment With Reduced Tissue In-Growth |
US20200146896A1 (en) * | 2018-11-08 | 2020-05-14 | Kci Licensing, Inc. | Dressing with protruding layer allowing for cleansing of wound bed macro deformations |
WO2020124038A1 (en) | 2018-12-13 | 2020-06-18 | University Of Massachusetts | Negative pressure wound closure devices and methods |
JP2022520048A (en) * | 2019-02-07 | 2022-03-28 | ケーシーアイ ライセンシング インコーポレイテッド | Contoured foam dressing shaped to provide negative pressure for the shoulder incision |
GB201903774D0 (en) | 2019-03-20 | 2019-05-01 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
GB201907716D0 (en) | 2019-05-31 | 2019-07-17 | Smith & Nephew | Systems and methods for extending operational time of negative pressure wound treatment apparatuses |
AU2020294577B2 (en) * | 2019-06-20 | 2023-09-28 | Kuo Huang YANG | Fluid-carrying application |
US20230301835A1 (en) * | 2020-07-30 | 2023-09-28 | 3M Innovative Properties Company | Low-growth tissue interface |
USD1043997S1 (en) * | 2020-09-18 | 2024-09-24 | Jake Timothy | Compression wound dressing |
Family Cites Families (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1355846A (en) | 1920-02-06 | 1920-10-19 | David A Rannells | Medical appliance |
US2547758A (en) * | 1949-01-05 | 1951-04-03 | Wilmer B Keeling | Instrument for treating the male urethra |
US2632443A (en) * | 1949-04-18 | 1953-03-24 | Eleanor P Lesher | Surgical dressing |
GB692578A (en) | 1949-09-13 | 1953-06-10 | Minnesota Mining & Mfg | Improvements in or relating to drape sheets for surgical use |
US2682873A (en) * | 1952-07-30 | 1954-07-06 | Johnson & Johnson | General purpose protective dressing |
NL189176B (en) | 1956-07-13 | 1900-01-01 | Hisamitsu Pharmaceutical Co | PLASTER BASED ON A SYNTHETIC RUBBER. |
US2969057A (en) * | 1957-11-04 | 1961-01-24 | Brady Co W H | Nematodic swab |
US2930377A (en) * | 1958-06-02 | 1960-03-29 | Baxter Don Inc | Surgical tube |
US3066672A (en) | 1960-09-27 | 1962-12-04 | Jr William H Crosby | Method and apparatus for serial sampling of intestinal juice |
US3407817A (en) | 1965-07-26 | 1968-10-29 | Air Reduction Inc | Catheter with cuff inflater and indicator |
US3367332A (en) * | 1965-08-27 | 1968-02-06 | Gen Electric | Product and process for establishing a sterile area of skin |
US3520300A (en) * | 1967-03-15 | 1970-07-14 | Amp Inc | Surgical sponge and suction device |
US3568675A (en) * | 1968-08-30 | 1971-03-09 | Clyde B Harvey | Fistula and penetrating wound dressing |
US3630206A (en) | 1970-01-02 | 1971-12-28 | Bruce Gingold | Bladder catheter |
US3599641A (en) * | 1970-03-13 | 1971-08-17 | David S Sheridan | Combination connector and channel closure system for catheters |
US3682180A (en) * | 1970-06-08 | 1972-08-08 | Coilform Co Inc | Drain clip for surgical drain |
BE789293Q (en) * | 1970-12-07 | 1973-01-15 | Parke Davis & Co | MEDICO-SURGICAL DRESSING FOR BURNS AND SIMILAR LESIONS |
US3826254A (en) * | 1973-02-26 | 1974-07-30 | Verco Ind | Needle or catheter retaining appliance |
DE2527706A1 (en) * | 1975-06-21 | 1976-12-30 | Hanfried Dr Med Weigand | DEVICE FOR THE INTRODUCTION OF CONTRAST AGENTS INTO AN ARTIFICIAL INTESTINAL OUTLET |
DE2640413C3 (en) | 1976-09-08 | 1980-03-27 | Richard Wolf Gmbh, 7134 Knittlingen | Catheter monitor |
NL7710909A (en) * | 1976-10-08 | 1978-04-11 | Smith & Nephew | COMPOSITE STRAPS. |
GB1562244A (en) | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
US4080970A (en) * | 1976-11-17 | 1978-03-28 | Miller Thomas J | Post-operative combination dressing and internal drain tube with external shield and tube connector |
US4139004A (en) * | 1977-02-17 | 1979-02-13 | Gonzalez Jr Harry | Bandage apparatus for treating burns |
US4184510A (en) * | 1977-03-15 | 1980-01-22 | Fibra-Sonics, Inc. | Valued device for controlling vacuum in surgery |
US4165748A (en) * | 1977-11-07 | 1979-08-28 | Johnson Melissa C | Catheter tube holder |
US4256109A (en) * | 1978-07-10 | 1981-03-17 | Nichols Robert L | Shut off valve for medical suction apparatus |
SE414994B (en) * | 1978-11-28 | 1980-09-01 | Landstingens Inkopscentral | VENKATETERFORBAND |
GB2047543B (en) * | 1978-12-06 | 1983-04-20 | Svedman Paul | Device for treating tissues for example skin |
US4266545A (en) | 1979-04-06 | 1981-05-12 | Moss James P | Portable suction device for collecting fluids from a closed wound |
US4284079A (en) * | 1979-06-28 | 1981-08-18 | Adair Edwin Lloyd | Method for applying a male incontinence device |
US4261363A (en) * | 1979-11-09 | 1981-04-14 | C. R. Bard, Inc. | Retention clips for body fluid drains |
US4569348A (en) * | 1980-02-22 | 1986-02-11 | Velcro Usa Inc. | Catheter tube holder strap |
ATE14835T1 (en) | 1980-03-11 | 1985-08-15 | Schmid Eduard | SKIN GRAFT PRESSURE BANDAGE. |
US4297995A (en) | 1980-06-03 | 1981-11-03 | Key Pharmaceuticals, Inc. | Bandage containing attachment post |
US4333468A (en) * | 1980-08-18 | 1982-06-08 | Geist Robert W | Mesentery tube holder apparatus |
US4398910A (en) * | 1981-02-26 | 1983-08-16 | Blake L W | Wound drain catheter |
US4465485A (en) * | 1981-03-06 | 1984-08-14 | Becton, Dickinson And Company | Suction canister with unitary shut-off valve and filter features |
US4392853A (en) * | 1981-03-16 | 1983-07-12 | Rudolph Muto | Sterile assembly for protecting and fastening an indwelling device |
SE8103617L (en) * | 1981-06-09 | 1982-12-10 | Meteve Ab | CATS FOR POST-OPERATIVE DRAINAGE |
US4373519A (en) * | 1981-06-26 | 1983-02-15 | Minnesota Mining And Manufacturing Company | Composite wound dressing |
US4392858A (en) * | 1981-07-16 | 1983-07-12 | Sherwood Medical Company | Wound drainage device |
US4419097A (en) | 1981-07-31 | 1983-12-06 | Rexar Industries, Inc. | Attachment for catheter tube |
AU550575B2 (en) | 1981-08-07 | 1986-03-27 | Richard Christian Wright | Wound drainage device |
SE429197B (en) * | 1981-10-14 | 1983-08-22 | Frese Nielsen | SAR TREATMENT DEVICE |
DE3146266A1 (en) * | 1981-11-21 | 1983-06-01 | B. Braun Melsungen Ag, 3508 Melsungen | COMBINED DEVICE FOR A MEDICAL SUCTION DRAINAGE |
US4551139A (en) | 1982-02-08 | 1985-11-05 | Marion Laboratories, Inc. | Method and apparatus for burn wound treatment |
US4475909A (en) | 1982-05-06 | 1984-10-09 | Eisenberg Melvin I | Male urinary device and method for applying the device |
EP0100148B1 (en) | 1982-07-06 | 1986-01-08 | Dow Corning Limited | Medical-surgical dressing and a process for the production thereof |
NZ206837A (en) | 1983-01-27 | 1986-08-08 | Johnson & Johnson Prod Inc | Thin film adhesive dressing:backing material in three sections |
US4548202A (en) | 1983-06-20 | 1985-10-22 | Ethicon, Inc. | Mesh tissue fasteners |
US4540412A (en) * | 1983-07-14 | 1985-09-10 | The Kendall Company | Device for moist heat therapy |
US4543100A (en) * | 1983-11-01 | 1985-09-24 | Brodsky Stuart A | Catheter and drain tube retainer |
US4525374A (en) * | 1984-02-27 | 1985-06-25 | Manresa, Inc. | Treating hydrophobic filters to render them hydrophilic |
GB2157958A (en) | 1984-05-03 | 1985-11-06 | Ernest Edward Austen Bedding | Ball game net support |
US4897081A (en) * | 1984-05-25 | 1990-01-30 | Thermedics Inc. | Percutaneous access device |
US5215522A (en) * | 1984-07-23 | 1993-06-01 | Ballard Medical Products | Single use medical aspirating device and method |
GB8419745D0 (en) * | 1984-08-02 | 1984-09-05 | Smith & Nephew Ass | Wound dressing |
US4872450A (en) | 1984-08-17 | 1989-10-10 | Austad Eric D | Wound dressing and method of forming same |
US4826494A (en) * | 1984-11-09 | 1989-05-02 | Stryker Corporation | Vacuum wound drainage system |
US4655754A (en) * | 1984-11-09 | 1987-04-07 | Stryker Corporation | Vacuum wound drainage system and lipids baffle therefor |
US4605399A (en) * | 1984-12-04 | 1986-08-12 | Complex, Inc. | Transdermal infusion device |
US5037397A (en) * | 1985-05-03 | 1991-08-06 | Medical Distributors, Inc. | Universal clamp |
US4640688A (en) * | 1985-08-23 | 1987-02-03 | Mentor Corporation | Urine collection catheter |
US4710165A (en) | 1985-09-16 | 1987-12-01 | Mcneil Charles B | Wearable, variable rate suction/collection device |
US4758220A (en) * | 1985-09-26 | 1988-07-19 | Alcon Laboratories, Inc. | Surgical cassette proximity sensing and latching apparatus |
US4733659A (en) * | 1986-01-17 | 1988-03-29 | Seton Company | Foam bandage |
WO1987004626A1 (en) | 1986-01-31 | 1987-08-13 | Osmond, Roger, L., W. | Suction system for wound and gastro-intestinal drainage |
US4838883A (en) * | 1986-03-07 | 1989-06-13 | Nissho Corporation | Urine-collecting device |
JPS62281965A (en) * | 1986-05-29 | 1987-12-07 | テルモ株式会社 | Catheter and catheter fixing member |
GB8621884D0 (en) * | 1986-09-11 | 1986-10-15 | Bard Ltd | Catheter applicator |
GB2195255B (en) | 1986-09-30 | 1991-05-01 | Vacutec Uk Limited | Apparatus for vacuum treatment of an epidermal surface |
US4743232A (en) * | 1986-10-06 | 1988-05-10 | The Clinipad Corporation | Package assembly for plastic film bandage |
DE3634569A1 (en) | 1986-10-10 | 1988-04-21 | Sachse Hans E | CONDOM CATHETER, A URINE TUBE CATHETER FOR PREVENTING RISING INFECTIONS |
JPS63135179A (en) * | 1986-11-26 | 1988-06-07 | 立花 俊郎 | Subcataneous drug administration set |
GB8628564D0 (en) | 1986-11-28 | 1987-01-07 | Smiths Industries Plc | Anti-foaming agent suction apparatus |
GB8706116D0 (en) * | 1987-03-14 | 1987-04-15 | Smith & Nephew Ass | Adhesive dressings |
US4787888A (en) | 1987-06-01 | 1988-11-29 | University Of Connecticut | Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a) |
US4863449A (en) * | 1987-07-06 | 1989-09-05 | Hollister Incorporated | Adhesive-lined elastic condom cathether |
US5176663A (en) * | 1987-12-02 | 1993-01-05 | Pal Svedman | Dressing having pad with compressibility limiting elements |
US4906240A (en) * | 1988-02-01 | 1990-03-06 | Matrix Medica, Inc. | Adhesive-faced porous absorbent sheet and method of making same |
US4985019A (en) * | 1988-03-11 | 1991-01-15 | Michelson Gary K | X-ray marker |
GB8812803D0 (en) | 1988-05-28 | 1988-06-29 | Smiths Industries Plc | Medico-surgical containers |
US4919654A (en) * | 1988-08-03 | 1990-04-24 | Kalt Medical Corporation | IV clamp with membrane |
US5000741A (en) | 1988-08-22 | 1991-03-19 | Kalt Medical Corporation | Transparent tracheostomy tube dressing |
DE69017479T2 (en) * | 1989-01-16 | 1995-07-13 | Roussel Uclaf | Azabicyclohepten derivatives and their salts, processes for their preparation, their use as medicaments and preparations containing them. |
GB8906100D0 (en) | 1989-03-16 | 1989-04-26 | Smith & Nephew | Laminates |
US5527293A (en) * | 1989-04-03 | 1996-06-18 | Kinetic Concepts, Inc. | Fastening system and method |
US5261893A (en) | 1989-04-03 | 1993-11-16 | Zamierowski David S | Fastening system and method |
US4969880A (en) | 1989-04-03 | 1990-11-13 | Zamierowski David S | Wound dressing and treatment method |
US5100396A (en) * | 1989-04-03 | 1992-03-31 | Zamierowski David S | Fluidic connection system and method |
US5358494A (en) | 1989-07-11 | 1994-10-25 | Svedman Paul | Irrigation dressing |
JP2719671B2 (en) * | 1989-07-11 | 1998-02-25 | 日本ゼオン株式会社 | Wound dressing |
US5232453A (en) * | 1989-07-14 | 1993-08-03 | E. R. Squibb & Sons, Inc. | Catheter holder |
GB2235877A (en) | 1989-09-18 | 1991-03-20 | Antonio Talluri | Closed wound suction apparatus |
US5134994A (en) * | 1990-02-12 | 1992-08-04 | Say Sam L | Field aspirator in a soft pack with externally mounted container |
US5092858A (en) * | 1990-03-20 | 1992-03-03 | Becton, Dickinson And Company | Liquid gelling agent distributor device |
JP2941918B2 (en) | 1990-09-19 | 1999-08-30 | テルモ株式会社 | Weighing device |
US5149331A (en) * | 1991-05-03 | 1992-09-22 | Ariel Ferdman | Method and device for wound closure |
US5278100A (en) * | 1991-11-08 | 1994-01-11 | Micron Technology, Inc. | Chemical vapor deposition technique for depositing titanium silicide on semiconductor wafers |
US5645081A (en) * | 1991-11-14 | 1997-07-08 | Wake Forest University | Method of treating tissue damage and apparatus for same |
US5636643A (en) * | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
US5279550A (en) * | 1991-12-19 | 1994-01-18 | Gish Biomedical, Inc. | Orthopedic autotransfusion system |
US5167613A (en) | 1992-03-23 | 1992-12-01 | The Kendall Company | Composite vented wound dressing |
FR2690617B1 (en) * | 1992-04-29 | 1994-06-24 | Cbh Textile | TRANSPARENT ADHESIVE DRESSING. |
GB9225581D0 (en) * | 1992-12-08 | 1993-01-27 | Courtaulds Plc | Wound dressings |
DE4306478A1 (en) | 1993-03-02 | 1994-09-08 | Wolfgang Dr Wagner | Drainage device, in particular pleural drainage device, and drainage method |
US6241747B1 (en) * | 1993-05-03 | 2001-06-05 | Quill Medical, Inc. | Barbed Bodily tissue connector |
US5342376A (en) * | 1993-05-03 | 1994-08-30 | Dermagraphics, Inc. | Inserting device for a barbed tissue connector |
US5344415A (en) * | 1993-06-15 | 1994-09-06 | Deroyal Industries, Inc. | Sterile system for dressing vascular access site |
US5437651A (en) * | 1993-09-01 | 1995-08-01 | Research Medical, Inc. | Medical suction apparatus |
US5549584A (en) * | 1994-02-14 | 1996-08-27 | The Kendall Company | Apparatus for removing fluid from a wound |
GB9411429D0 (en) | 1994-06-08 | 1994-07-27 | Seton Healthcare Group Plc | Wound dressings |
US5556375A (en) * | 1994-06-16 | 1996-09-17 | Hercules Incorporated | Wound dressing having a fenestrated base layer |
US5607388A (en) * | 1994-06-16 | 1997-03-04 | Hercules Incorporated | Multi-purpose wound dressing |
US5664270A (en) | 1994-07-19 | 1997-09-09 | Kinetic Concepts, Inc. | Patient interface system |
PT853950E (en) | 1994-08-22 | 2003-03-31 | Kinetic Concepts Inc | WASTE DRAIN BOX |
DE29504378U1 (en) | 1995-03-15 | 1995-09-14 | MTG Medizinisch, technische Gerätebau GmbH, 66299 Friedrichsthal | Electronically controlled low-vacuum pump for chest and wound drainage |
GB9523253D0 (en) | 1995-11-14 | 1996-01-17 | Mediscus Prod Ltd | Portable wound treatment apparatus |
US6099513A (en) * | 1996-08-27 | 2000-08-08 | Allegiance Corporation | Wound drain with alternating perimetrically arranged lumens and ducts |
NL1006457C2 (en) | 1997-07-03 | 1999-01-05 | Polymedics N V | Drainage system to be used with an open wound, element used for applying a drainage pipe or hose and method for applying the drainage system. |
US6135116A (en) | 1997-07-28 | 2000-10-24 | Kci Licensing, Inc. | Therapeutic method for treating ulcers |
US7273054B2 (en) * | 1997-09-12 | 2007-09-25 | Kci Licensing, Inc. | Surgical drape and head for wound treatment |
AU755496B2 (en) | 1997-09-12 | 2002-12-12 | Kci Licensing, Inc. | Surgical drape and suction head for wound treatment |
GB9719520D0 (en) | 1997-09-12 | 1997-11-19 | Kci Medical Ltd | Surgical drape and suction heads for wound treatment |
US6071267A (en) * | 1998-02-06 | 2000-06-06 | Kinetic Concepts, Inc. | Medical patient fluid management interface system and method |
US6488643B1 (en) | 1998-10-08 | 2002-12-03 | Kci Licensing, Inc. | Wound healing foot wrap |
US6287316B1 (en) * | 1999-03-26 | 2001-09-11 | Ethicon, Inc. | Knitted surgical mesh |
US7799004B2 (en) | 2001-03-05 | 2010-09-21 | Kci Licensing, Inc. | Negative pressure wound treatment apparatus and infection identification system and method |
US6856821B2 (en) * | 2000-05-26 | 2005-02-15 | Kci Licensing, Inc. | System for combined transcutaneous blood gas monitoring and vacuum assisted wound closure |
US6991643B2 (en) * | 2000-12-20 | 2006-01-31 | Usgi Medical Inc. | Multi-barbed device for retaining tissue in apposition and methods of use |
US6478789B1 (en) | 1999-11-15 | 2002-11-12 | Allegiance Corporation | Wound drain with portals to enable uniform suction |
AU4176101A (en) | 2000-02-24 | 2001-09-03 | Venetec Int Inc | Universal catheter anchoring system |
US6685681B2 (en) * | 2000-11-29 | 2004-02-03 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
US7700819B2 (en) * | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US6540705B2 (en) * | 2001-02-22 | 2003-04-01 | Core Products International, Inc. | Ankle brace providing upper and lower ankle adjustment |
US7004915B2 (en) * | 2001-08-24 | 2006-02-28 | Kci Licensing, Inc. | Negative pressure assisted tissue treatment system |
WO2004018020A1 (en) * | 2002-08-21 | 2004-03-04 | Hill-Rom Services, Inc. | Wound packing for preventing wound closure |
US7846141B2 (en) * | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
US6979324B2 (en) * | 2002-09-13 | 2005-12-27 | Neogen Technologies, Inc. | Closed wound drainage system |
US7154017B2 (en) * | 2002-12-31 | 2006-12-26 | Ossur Hf | Method for producing a wound dressing |
GB0409443D0 (en) * | 2004-04-28 | 2004-06-02 | Smith & Nephew | Apparatus |
DE102004001594B4 (en) * | 2004-01-09 | 2006-09-21 | Bio-Gate Ag | Wound dressing and process for its preparation |
US7754937B2 (en) * | 2004-03-18 | 2010-07-13 | Boehringer Technologies, L.P. | Wound packing material for use with suction |
US7951124B2 (en) * | 2004-04-13 | 2011-05-31 | Boehringer Technologies, Lp | Growth stimulating wound dressing with improved contact surfaces |
US7884258B2 (en) * | 2004-04-13 | 2011-02-08 | Boehringer Technologies, L.P. | Wound contact device |
GB2415382A (en) * | 2004-06-21 | 2005-12-28 | Johnson & Johnson Medical Ltd | Wound dressings for vacuum therapy |
US7438705B2 (en) * | 2005-07-14 | 2008-10-21 | Boehringer Technologies, L.P. | System for treating a wound with suction and method detecting loss of suction |
US7879615B2 (en) * | 2005-10-20 | 2011-02-01 | Coramed Technologies, Llc | Hemostasis analyzer and method |
AU2007206054B2 (en) * | 2006-01-23 | 2011-06-09 | 3M Innovative Properties Company | System and method for treating a wound using ultrasonic debridement |
AU2007212480B2 (en) | 2006-02-06 | 2010-04-29 | Solventum Intellectual Properties Company | Systems and methods for improved connection to wound dressings in conjunction with reduced pressure wound treatment systems |
WO2007092405A2 (en) * | 2006-02-07 | 2007-08-16 | Tyco Healthcare Group Lp | Surgical wound dressing |
NZ576472A (en) * | 2006-09-26 | 2011-12-22 | Boehringer Technologies Lp | Pump system for negative pressure wound therapy |
EP2079418B1 (en) * | 2006-11-09 | 2014-07-16 | KCI Licensing, Inc. | Porous bioresorbable dressing conformable to a wound and methods of making same |
WO2008104609A1 (en) * | 2007-03-01 | 2008-09-04 | Coloplast A/S | Pressure-distributing elements for use with negative pressure therapy |
CN101801311A (en) | 2007-05-01 | 2010-08-11 | 布赖汉姆妇女医院有限公司 | Wound healing device |
JP5243526B2 (en) * | 2007-05-10 | 2013-07-24 | ケーシーアイ ライセンシング インコーポレイテッド | Depressurized wound dressing comprising a wound contact surface having columnar protrusions |
GB0724039D0 (en) * | 2007-12-08 | 2008-01-16 | Smith & Nephew | Wound fillers |
GB0724040D0 (en) * | 2007-12-08 | 2008-01-16 | Smith & Nephew | Wound packing members |
AU2009251242B2 (en) * | 2008-05-30 | 2013-08-15 | Solventum Intellectual Properties Company | Super-absorbent, reduced-pressure wound dressing and systems |
-
2009
- 2009-12-16 US US12/639,253 patent/US8529528B2/en active Active
- 2009-12-17 SG SG2011041555A patent/SG172011A1/en unknown
- 2009-12-17 EP EP20150173.1A patent/EP3669850A1/en not_active Withdrawn
- 2009-12-17 MX MX2011006806A patent/MX2011006806A/en not_active Application Discontinuation
- 2009-12-17 RU RU2011122962/14A patent/RU2011122962A/en not_active Application Discontinuation
- 2009-12-17 EP EP17197927.1A patent/EP3292854B1/en active Active
- 2009-12-17 WO PCT/US2009/068544 patent/WO2010075179A2/en active Application Filing
- 2009-12-17 CA CA2745695A patent/CA2745695C/en active Active
- 2009-12-17 KR KR1020117017298A patent/KR20110116140A/en not_active Application Discontinuation
- 2009-12-17 EP EP09835646.2A patent/EP2367518B1/en active Active
- 2009-12-17 AU AU2009330298A patent/AU2009330298B2/en active Active
- 2009-12-17 BR BRPI0918310A patent/BRPI0918310A2/en not_active IP Right Cessation
- 2009-12-17 CN CN200980151961.XA patent/CN102264333B/en active Active
- 2009-12-17 JP JP2011543594A patent/JP5613173B2/en active Active
- 2009-12-24 TW TW098144834A patent/TW201029697A/en unknown
-
2013
- 2013-08-09 US US13/963,809 patent/US9622915B2/en active Active
-
2015
- 2015-12-31 AU AU2015285968A patent/AU2015285968B2/en active Active
-
2017
- 2017-03-03 US US15/448,793 patent/US10561768B2/en active Active
-
2020
- 2020-01-02 US US16/733,055 patent/US20200147280A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2015285968B2 (en) | 2017-06-01 |
EP2367518A2 (en) | 2011-09-28 |
CN102264333B (en) | 2014-08-27 |
BRPI0918310A2 (en) | 2019-09-24 |
SG172011A1 (en) | 2011-07-28 |
WO2010075179A2 (en) | 2010-07-01 |
AU2015285968A1 (en) | 2016-02-04 |
AU2009330298A1 (en) | 2010-07-01 |
CA2745695C (en) | 2017-09-19 |
MX2011006806A (en) | 2011-07-12 |
US20100160874A1 (en) | 2010-06-24 |
CN102264333A (en) | 2011-11-30 |
AU2009330298B2 (en) | 2015-10-08 |
EP2367518B1 (en) | 2017-10-25 |
KR20110116140A (en) | 2011-10-25 |
JP5613173B2 (en) | 2014-10-22 |
US9622915B2 (en) | 2017-04-18 |
RU2011122962A (en) | 2013-01-27 |
US20130324951A1 (en) | 2013-12-05 |
EP2367518A4 (en) | 2016-03-09 |
WO2010075179A3 (en) | 2010-10-07 |
EP3292854A1 (en) | 2018-03-14 |
EP3292854B1 (en) | 2020-02-12 |
US10561768B2 (en) | 2020-02-18 |
US20170224889A1 (en) | 2017-08-10 |
JP2012513825A (en) | 2012-06-21 |
EP3669850A1 (en) | 2020-06-24 |
CA2745695A1 (en) | 2010-07-01 |
TW201029697A (en) | 2010-08-16 |
US8529528B2 (en) | 2013-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10987454B2 (en) | Reduced-pressure wound treatment systems and methods employing manifold structures | |
US10561768B2 (en) | Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds | |
US9421309B2 (en) | Reduced-pressure treatment systems and methods employing hydrogel reservoir members |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: KCI LICENSING, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROBINSON, TIMOTHY MARK;LOCKE, CHRISTOPHER BRIAN;TOUT, AIDAN MARCUS;SIGNING DATES FROM 20111021 TO 20111024;REEL/FRAME:052395/0134 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |